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“…… 
We are not now that strength which in old days 
Moved earth and heaven, that which we are, we are; 
One equal temper of heroic hearts, 
Made weak by time and fate, but strong in will 
To strive, to seek, to find, and not to yield.” 
--- Ulysses, by Alfred, Lord Tennyson
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ABSTRACT 
          Nanoparticles (NPs) are becoming increasingly popular as a new tool for the 
investigation of virus trafficking pathways and the delivery of therapeutic agents into 
targeted recipient cells. However, one general challenge for applications of NPs in the 
biological context is that a broad variety of different proteins can adsorb to the NP surface. 
The resulting formation of a so-called “corona” around NPs impacts the fate and 
distribution of NPs both in vitro and in vivo due to nonspecific opsonization and 
scavenging. Inspired by the surface compositions of living cells and enveloped viruses, 
here in this dissertation, a NP passivation strategy based on a self-assembled lipid 
membrane containing phospholipids such as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC) and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) is developed and 
evaluated. The effect of the DPPC / DOPS ratio on corona formation is systematically 
analyzed. After inclusion of monosialoldihexosyl-ganglioside GM3, which binds 
selectively to CD169 (Siglec-1) expressed by myeloid cells such as macrophages and 
dendritic cells, into the membrane coating, NPs are found to target CD169 expressing 
 macrophages in mouse lymph nodes in vivo. Combined in vitro and in vivo studies show 
that lipid-wrapped NPs represent a versatile platform for utilizing specific lipid–receptor 
interactions for targeting purposes. 
           Presentation of GM3 on NPs achieves a recapitulation of the intracellular 
distribution observed for human immunodeficiency virus type 1 (HIV-1) in CD169 
expressing macrophages and dendritic cells. Therefore, membrane-wrapped NPs are 
referred to as artificial virus nanoparticles (AVN). We demonstrate that AVN can 
accumulate in virus containing compartments (VCC), which are deep plasma membrane 
invaginations in macrophages that provide evasion for HIV-1 from the immune system and 
anti-viral therapeutics. Intriguingly, the ability to target VCC depended exquisitely on the 
GM3/DOPS ratio in the AVN membrane. 
           Exchange of gold NPs with mesoporous silica NPs provides a new class of AVN 
whose core can serve as matrix and also carry therapeutic agents. We show using rilpivirine 
(RPV), a FDA approved second-generation non-nucleoside reverse transcriptase inhibitor 
of HIV-1 infection, that AVN with mesoporous NP core achieve significantly enhanced 
HIV-inhibition effects compared with soluble RPV or long-acting nanocrystalline 
formulation of RPV.  
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Chapter 1 INTRODUCTION      
Due to their small size, large surface-to-volume ratio and in some cases electron 
confinement, the properties of nano-materials can differ from those of the corresponding 
bulk materials. Nano-materials have found numerous applications in different scientific 
and engineering fields, including biophysics and biomedical research.(1–5). 
Nanoparticles (NPs) are defined as ‘solid colloidal particles ranging in size from 10 to 
1000 nm (1 μm). The range of uses of NPs in current medical and biological research is 
extremely broad. In particular, it includes genomics; biosensorics; immunoassay; clinical 
chemistry; detection and photothermolysis of microorganisms and cancer cells; targeted 
delivery of drugs, peptides, DNA, and antigens; and optical bioimaging and monitoring 
of cells and tissues with the use of state-of-the-art nanophotonic recording systems(6, 7). 
This introduction is aimed to first provide a basic review of fundamental physical and 
chemical properties of especially plasmonic NPs, which were predominantly used in this 
work. Current passivation strategies to stabilize these NPs in real bio-medical 
applications will also be covered. Finally, a specific ligand-receptor pair, Ganglioside 
(GM3)-Siglec 1 (CD169), will be introduced, which forms the basis for a lipid-mediated 
selective targeting of NPs to CD169-expressing macrophages and dendritic cells. 
1.1 Plasmonic Nanoparticle 
Among all plasmonic nano-materials,  gold (Au) and silver (Ag) NPs  are particularly 
useful for sensing and imaging approaches as they combine well-established size- and 
shape-controlled synthesis strategies, chemical stability (especially in the case of gold) 
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and large scattering cross-sections and extreme photophysical stability(8). The brightness 
and photostability of virus-sized plasmonic NPs makes them easily optically detectable 
through conventional dark-field microscopy. Unlike traditional fluorescent probes widely 
 
Figure 1.1 Plasmon coupling between Au NPs immunolables showing the lateral distribution of 
CD24 and CD44 
a) distribution of CD24 on SKBR3 cells, (b) distribution of CD24 on MCF7 cells, and (c) 
distribution of CD24 on MCF7 cells. (d) magnified view showing the color of Au NPs 
immunolabeling cluster (e) SEM shows the clusters of varying sizes (CD24 on MCF7 cells). (f) 
Exemplary spectra of individual spots on the cell surface. Size bars are 5 μm for (a–c) and 1 μm 
for (d–e). Reprinted with permission from ref. 12.  © 2013 American Chemical Society.  
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used in biological studies, plasmonic NPs do not blink or bleach. The size and shape of 
gold nanoparticles can be well controlled using established synthesis procedures(9, 10), 
providing a convenient strategy to change the color of the nanoparticles.  The scattering 
intensity of a 60nm gold particle is 105 times stronger than the fluorescence signal of a 
fluorescein molecule(8).  All these remarkable photophysical properties of plasmonic NPs 
further make them superb probes for optical imaging and particle tracking. 
In addition to individual plasmonic NPs, it is also worthwhile stressing the plasmon 
coupling effect, which results from the electromagnetic interactions from two or more 
plasmonic NPs. Upon the occurrence of plasmon coupling, the resonance of individual 
NPs start to hybridize, and their resonance spectra peak wavelength will redshift and the 
magnitude of the spectra redshift is dependent on the inter-particle gap as well as the 
agglomeration states(11). A larger redshift is usually associated with smaller inter-
particle gap and larger cluster size. Such distance and size dependent behavior of 
plasmonic NPs are found to be extremely useful in the studies of clustering behavior of 
biomolecules such as cell surface receptors and understanding the ligand-receptor 
trafficking mechanism upon the successful ligand-receptor binding (12, 13). Figure 1.1 
shows gold NPs based plasmon effect is utilized to map out the lateral distribution of 
CD24 and CD44 receptors on cell surface, noting the particle cluster sizes influence the 
corresponding color and spectra under dark-field microscopy. 
4 
 
In general, the advantageous and tunable photophysical properties of Au NPs and the 
easy surface modification through robust Au-thiol chemistry make Au NPs versatile 
probes in bio-imaging and theranostics (3–5).  
1.2 Nanoparticle Passivation 
As previously mentioned, targeting of NPs to selected cell populations through specific 
ligand – receptor interactions is central for NP applications in drug delivery and NP-based 
imaging. However, one general challenge for all active NP targeting methods, is that in 
biological fluids a broad variety of different proteins rapidly adsorb to the charged NP 
surface(14–17). The resulting formation of a “corona” around the NPs impacts the fate and 
distribution of NPs in vivo, since non-specific protein adsorption can cover NP-bound 
surface ligands and, thus, result in a reduction of their bio-availability and trigger ligand 
unrelated biological responses. Moreover, corona coated NPs are more likely to be taken 
up by macrophages rapidly and their blood circulation time could be significantly 
attenuated (18, 19). The potential decrease in binding selectivity and specificity related to 
corona formation in biological fluids necessitates the passivation and stabilization of NPs. 
The conventional strategy for passivating NPs and suppressing corona effects is based on 
PEGylation(20, 21). Figure 1.2 shows the schematic structure of PEGylated 40nm Au NPs 
from reference 16. Two kinds of PEGs are used here, HS–(CH2)11–(C2H4O)6–COOH (PEG1) 
and HS–CH2CH2–(C2H4O)77–N3 (PEG2). Such a combination was used to create a brush of 
(under physiological conditions)  negatively charged PEG1 molecules interspersed with azide-
containing PEG2 molecules, which can be crosslinked with epidermal growth factor (EGF) 
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peptides through the Cu(I) catalyzed 1,3-dipolar cycloaddition reaction. PEGs have 
demonstrated to suppress corona formation around NPs(22, 23), and they are also widely 
used in NP vaccines(24). Several studies have, however, indicated that PEGs are 
immunogenic(25–27) and reduce intracellular uptake(28–30) and transfection 
efficiency(31).  Furthermore, in the case of lipid-mediated targeting, especially for lipids 
with relatively small headgroups as targeting functionality, loss of activity through bulky 
PEGs that bury the active sites in a membrane is a major concern. In Figure 1.2, PEG2 is 
much longer than PEG1 to ensure that the tethered EGF was readily bioavailable and not 
covered by the PEG1 brush. All of these points together prompted our interest in enhancing 
the efficacy of NP- targeting strategies.  
Inspired by the surface compositions of living cells and enveloped viruses, another natural 
way to passivate and stabilize the NPs could be achieved through wrapping a lipid 
 
Figure 1.2 A PEGylation approach to stabilize NPs and conjugate EGF onto the NP surface 
PEG1 is HS–(CH2)11–(C2H4O)6–COOH and PEG2 is HS–CH2CH2–(C2H4O)77–N3. PEG1 is negatively 
charged to retain the colloidal stability under physiological conditions while PEG2 is mainly for 
introducing binding sites for EGF through azide-alkyne click chemistry. Reprinted with permission 
from ref. 23.  © The Royal Society of Chemistry 2014.  
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membrane, composed of common phospholipids, around the NP core and assemble them 
as a virus-like nano-structure.  Many lipids, such as phosphatidylcholine are zwitterionic 
and self-assembled monolayers of zwitterionic ligands have shown great promise for 
effectively suppressing corona formation around a wide variety of NPs(32–36).  The lipid 
wrapping strategy not only provides the NPs with the capability to affect the corona 
formation and further suppress it but also endows the NPs with the potential of lipid based 
selective targeting.  
1.3 Lipid Based Targeting – the Interaction between Siglec-1(CD169) and 
Ganglioside GM3  
In addition to conventional antibodies, peptides, aptamers and small molecules, lipids 
provide a valuable targeting functionality with a series of advantages related to 
solubilization, encapsulation and surface modification(37). Recent findings suggest that 
some gangliosides, i.e. glycosphingolipids with at least one sialic acid, enhance the 
targeting of enveloped human immunodeficiency virus (HIV-1) to specific host cells 
(refs?). These findings have generated significant interest in these glycolipids as alternative 
targeting functionalities for NPs(38–41).  A series of recent studies have shown that the 
sialyllactose group of gangliosides, such as the monosialoldihexosyl-ganglioside GM3, 
facilitates a selective binding of GM3-presenting NPs to Siglec1 (CD169)-expressing 
myeloid dendritic cells and macrophages(38, 42–45). This particular set of antigen 
presenting cells (APCs) plays a key role in priming and activating B cells(46–49), 
iNKT(39, 50), and CD8+ T(51–53) cells, and the selective targeting of the above-
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mentioned cells provides new opportunities for enhancing cell-mediated immunity and for 
improving vaccination efficacy.  
Intriguingly, GM3-CD169 mediated binding of NP to mature monocyte-derived dendritic 
cells (mDC) and macrophages triggers a unique compartmentalization of NPs in peripheral 
 
Figure 1.3 GM3-CD169 mediated NP compartmentalization in mDCs-Tcell conjugates 
The cells were stained for CD169 (a), CD81 (b), and F-actin (c). The left row shows the dark-field 
color image, the middle row the fluorescence image, and the right row a false-color overlay. T 
cells were stained with CellTracker Orange and are plotted in cyan pseudocolor. Nuclei were 
stained with DAPI fluorescence stain and are marked blue. Scale bars = 1 μm.  Reprinted with 
permission from ref. 34. © 2015 American Chemical Society 
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non-endolysosomal membrane compartments that attract surface scanning T cells(40, 41) 
(Figure 1.3) , which suggests that key steps in HIV-1 trans-infection, a process in which 
virus is transmitted to T cell hosts via dendritic cells or macrophages, are driven by GM3-
CD169 recognition and can occur in a viral glycoprotein gp120 independent fashion(54) . 
Furthermore, the ganglioside receptor CD169 orchestrates the accumulation of exogenous 
virus particles in apparently intracellular compartments, so-called virus containing 
compartments (VCC) in macrophages and mDC. With their unique structure and non-
endolysosomal nature, VCC are considered an ideal reservoir for the virus to evade the 
host’s immune system (55–57) and form a major obstacle for the eradication of HIV-1 with 
conventional combination antiretroviral therapy (cART), either due to long-term 
preservation of infectious virus particles, or decreased efficiency of anti-retrovirals to 
inhibit cell-associated HIV transmission(58, 59).  
In addition to enabling the active lipid based active targeting towards APCs, the 
incorporation of GM3 into the lipid membrane around the NPs, a tunable lipid membrane 
composition and a switchable NP core all together could develop such lipid membrane 
wrapped NPs into a model system that contributes to understanding the mechanism of GM3 
mediated HIV-1 infection and VCC formation and could further motivate future studies to 
evaluate the possibility to eradicate HIV-1 with NPs based antiretroviral drugs from those 
VCC. 
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Beside GM3, a common lipid, phosphatidylserine(PS) is also contained in the viral 
envelope and is a cofactor in the infection of monocytic cells by HIV-1(60). By presenting 
PS on its surface, a virus particle imitates apoptotic cellular debris. Through such 
established viral apoptotic mimicry, HIV-1 could further enhance host cell binding, 
infection, and replication(61, 62). However, with both PS and GM3 presenting on the 
surface, it is unclear how they interact with each other to contribute to the HIV-1 
glycoprotein independent infection approach. 
1.4 The Scope and Organization of this Dissertation 
The work introduced in this thesis mainly focuses on the applications of lipid membrane 
coated NPs as model system to investigate glycoprotein-independent targeting of human 
immune cells and mimic HIV viral uptake and trafficking.  
In chapter 2, the design and synthesis of lipid coated NPs will be evaluated. A systematic 
comparison of such lipid coated NPs with different membrane composition with the 
benchmark PEGylated NPs will be conducted to assess the effect of the membrane on the 
corona formation in simulated biological fluids in vitro. A fundamental understanding of 
how the lipid membrane affects corona formation around the NPs will be established and 
we will elaborate how the membrane can affect the GM3-CD169 based selective targeting 
functionality in an in vivo mouse model.  
After the working principles of lipid coated NPs in the bio-medical and biological research 
have been established in chapter 2, in chapter 3, such lipid coated NPs will be taken as a 
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model system to investigate the role of GM3 and phosphatidylserine (PS) in targeting the 
NPs towards the VCC in human macrophages. We will demonstrate that these lipid coated 
NPs can successfully recapitulate the intracellular distribution observed for HIV-1 in 
dendritic cells and macrophages. Therefore, lipid membrane coated NPs are referred to as 
artificial virus nanoparticles (AVNs). Furthermore, the role of the core inside the AVN 
structure is probed as well in term of altering the final fate of AVN inside the macrophages. 
As VCC are HIV assembly and accumulation sites, GM3-presenting AVN define a rational 
strategy for targeting a putative viral reservoir in macrophages and provides new 
opportunities for addressing viral persistence. 
In chapter 4, the gold core of AVN will be exchanged with mesoporous silica, which serves 
as a matrix to carry therapeutic agents. In this way, the AVN are endowed with delivery 
functions in addition to just targeting specific recipient cells. We show using rilpivirine 
(RPV), a FDA approved second-generation non-nucleoside reverse transcriptase inhibitor 
for HIV-1 infection, that the meso-porous based AVN achieve significantly enhanced HIV-
inhibition compared with soluble RPV or long-acting RPV nanocrystals. Through the 
systematic design and investigation of the AVN model and the comparison of AVN model 
with HIV-1, we pave the way for a future potent design to practically address the HIV-1 
persistence problem and to eradicate HIV-1 from human immune cells with AVN-
formulated antiretroviral drugs.   
This thesis includes material from two papers published by the author. Chapter 2 is 
reproduced with permission from reference (63), reproduced with permission, © 2015 
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American Chemical Society. Chapter 3 is based on unpublished work that was recently 
submitted for publication considerations. Chapter 4 is based on the current unpublished 
work. 
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Chapter 2 LIPID MEMBRANE WRAPPED NANOAPARTICLES: DESIGN, 
SYNTHESIS, CORONA FORMATION AND THEIR APPLICATIONS IN LIPID 
MEDIATED TARGETING 
The lipid membrane wrapped around the NPs provides a versatile platform to incorporate 
the lipid-like ganglioside GM3 molecule and endow such GM3-presenting NPs with 
targeting functionality for Siglec1 (CD169)-expressing myeloid dendritic cells and 
macrophages. As they are conceptually similar to enveloped virus particles, which are 
also encapsulated in a lipid membrane based shell, we refer to these hybrid NPs as 
artificial virus NPs (AVNs) (40, 41) throughout the thesis. However, it should not be 
overlooked that once the NPs endowed with the targeting functionality face the practical 
application in the real biological fluids, a large variety of different proteins could rapidly 
bind to the charged NPs surface in a unspecific fashion (14–17) and then form the so-
called “corona” around the NPs. Such corona impacts the fate and interferes with the 
original functionality of NPs in the biological context since non-specific protein 
adsorption can cover NP-bound surface ligands and, thus, result in a reduction of their 
bio-functionality and bio-availability and could even trigger ligand unrelated biological 
responses(64).  
One of the benchmark strategy that has been widely employed to suppress the corona 
formation around the NPs is to use PEGs (poly(ethylene glycol)s) to coat the NPs and 
such a strategy has been demonstrated to suppress the corona formation(22). In this 
chapter, we will use PEGylated NPs as the benchmark with which we will compare 
AVNs’ performance to affect the corona formation. In the rest of this chapter, we will 1). 
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lay out the synthesis Au NPs based GM3 containing AVNs, 2). characterize the AVN and 
the nonspecific protein adsorption to GM3-containing AVNs (GM3-AVN) with a 35 and 
80 nm core, 3). evaluate the effect of NP core size and membrane charge on corona 
formation and CD169 targeting selectivity in vitro, 4). test the stability of the AVN 
membrane in complex biological environments, and 5). validate the ability of optimized 
GM3-AVN particles to target CD169+ macrophages in popliteal lymph nodes after hock 
injection in a murine immunization model (in vivo). 
2.1 Synthesis & Characterization of Au NPs Based GM3 Containing AVNs  
In general, AVNs were generated by integrating lipids via their hydrophobic tail into an 
octadecanethiol monolayer self-assembled around a 35 or 80 nm diameter gold NP core.  
We applied a “one-pot” assembly (40, 65) strategy in which a citrate-stabilized gold 
colloid derived from the Turkevich method(66, 67) was incubated with octadecanethiol 
and liposomes were used as lipid reservoir to generate AVNs (Figure 2.1). The detailed 
lipid membrane composition in our design of AVNs is inspired by enveloped virus 
particles, such as the human immunodeficiency virus (HIV) to achieve the combinative 
goals of repelling corona plus effective GM3-CD169 targeting. The composition of the 
liposomes (≥55 mol % 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), ∼40 mol 
% cholesterol) was, consequently, chosen to imitate the basic membrane properties of 
enveloped HIV particles (68). GM3 (3 mol %) was included for targeting purposes. 
DPPC was selected as the bulk component due to its zwitterionic nature and small 
14 
 
headgroup size (Figure 2.1), which could minimize any potential interference with the 
CD169-binding sialyllactose group of GM3. We found that a small concentration of 
negatively charged lipid was necessary to ensure the colloidal stability of the AVNs thus 
  
 
 
(a) Schematic overview of AVN preparation. (b) Molecular structures of DPPC, DOPS, GM3, 
and cholesterol and their respective concentrations in the liposomes. Reprinted with permission 
from ref. 64. © 2016 American Chemical Society. 
Figure 2.1 Schematic Overview of AVN preparation and structure 
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we added 1–5 mol % 1,2-dioleoyl-sn-glycero-3-phospho-l-serine (DOPS) in a systematic 
fashion to vary the surface charge of the AVNs. 
As shown in the structure of AVNs in the Figure 2.1, octadecanethiol binds readily to the 
Au core surface and establishes a hydrophobic surface onto which lipids from co-
incubated liposomes can spread, anchor and further form lipid membrane. To confirm the 
structural model of lipid membrane wrapped NPs, we also added a lipid dye (0.1 mol % 
16:0 Liss Rhod PE) into the membrane thus the optical co-localization of the 
fluorescence signal with the dark-field scattering from the Au core could be applied to 
validate the existence of membrane around the Au core. In Figure 2.2, the almost 100% 
co-localization of fluorescent against dark-field signals confirms a successful wrapping of 
membrane around the Au core.  
Before characterizing AVN’s performance in affecting the corona formation, it should be 
emphasized that the chemical composition of the surface plus the surface charge are key 
factors that could potentially affect corona formation around NPs (16). We first use the 
  
 
Left: darkfield image of the Au NP core; Middle: Fluorescence image of lipid membrane; Right: 
Composite image of darkfield and fluorescence. Scale bar: 5 μm.  
Figure 2.2 Co-localization of AVN. Co-localization between lipid membrane and Au NP core 
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negatively charged DOPS to tune the surface charge of the AVNs in a systematic fashion. 
Furthermore, the NP size can modulate the corona formation due to curvature-related 
changes in the membrane composition and NP–protein interactions(16, 17). For the sake 
of simplicity, we limited our investigation to two representative NP core sizes (35nm & 
80nm, AVN35 and AVN80) in the characteristic size range of most virus particles. 
As PEGs are widely employed as a conventional strategy to stabilize the NPs in the bio-
medical field, an alternative PEG based ligand of similar size to the lipids that can 
stabilize 35–80 nm diameter NPs against agglomeration in the typical biological buffers 
is the alkyl-PEG-carboxylic acid HS-(CH2)11-EG6-OCH2-COOH (69, 70). We included 
NPs passivated with these PEGs as a benchmark for nonspecific protein adsorption, as 
the resulting NPs have similar zeta potentials to AVNs dosed with 5% DOPS (Table 1). 
We refer to these NPs as PEG-NP throughout this chapter. The zeta potentials of all NPs 
discussed in this chapter are summarized in Table 1. 
 
 
 
 
 
 
 
 
 
Nanoparticle ζ (mV) 
1mol% DOPS  AVN35 -12.9±2.0 
2mol% DOPS AVN35 -21.9±1.5 
5mol% DOPS AVN35 -30.1±3.0 
1mol% DOPS AVN80 -14.9±1.9 
2mol% DOPS AVN80 -26.0±0.3 
5mol% DOPS AVN80 -30.6±1.1 
PEG-NP (35nm) -30.7±3.0 
PEG-NP (80nm) -35.0±0.9 
Table 1. Zeta Potentials (ζ) for All Investigated NPs 
in Distilled Deionized (DDI) Water 
Table 1. Zeta Potentials (ζ) for Al  Investigated NPs in 
Distilled Deionized (DDI) Water 
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The data confirm that variation of the DOPS concentration in the AVN membrane leads 
to a systematic variation of the AVN surface charge between approximately −10 and −30 
mV. Another important finding should not be ignored is that the resulting PEG-NPs have 
similar zeta potentials to AVNs dosed with 5% DOPS, which legitimizes a fair 
comparison between AVNs and PEG-NPs in investigating the corona formation.  
2.2 Corona Formation around Au AVNs in Vitro  
As previously discussed, nonspecific NP–protein interactions lead to corona formation 
and such corona could be classified as hard (nonreversible binding) or soft (reversible 
binding) corona (16, 71).Corona formation around NPs is frequently studied in vitro 
under standardized cell growth conditions (10% fetal bovine serum (FBS) in Dulbecco’s 
modified Eagle medium (DMEM) at 37 °C) (72–75).To facilitate comparability with 
well-established studies and for the sake of simplicity, we applied the same conditions 
and characterized the corona formation through measuring hydrodynamic radii and the 
zeta potentials for AVN35 and AVN80 containing three different DOPS concentrations 
(1, 2, and 5 mol %). To differentiate the soft and hard corona for the investigated AVNs, 
we measured also hydrodynamic diameter (Dhyd) of the AVNs under three different 
experimental conditions: (i) before addition to FBS containing medium (no corona), (ii) 
after incubation in FBS containing medium for 24 h (hard + soft corona, without any 
washing procedures), and (iii) after removal of the soft corona through centrifugation and 
resuspension in water (hard corona) (76). For all conditions we referenced PEG-NPs as a 
benchmark. 
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Representative distributions of the hydrodynamic diameter as determined by dynamic light 
scattering (DLS) for the investigated AVN35 and AVN80 are summarized in Figure 2.3a 
and Figure 2.3b, respectively. For all AVN35, a large (ΔDhyd ≈ 100 nm) shift of the 
average hydrodynamic diameter is observed upon incubation in FBS containing medium 
(Figure 2.3a, middle, hard + soft corona). While the differences in ΔDhyd between the three 
AVN35 preparations lie within the range of typical experimental fluctuations associated 
with the preparations of AVNs, the shift for the PEG-NPs is (ΔDhyd ≈  200 nm) 
significantly larger than for all AVN35 conditions, including AVN35 with 5 mol % DOPS, 
whose zeta potentials are comparable to those of PEG-NPs (Table 1). Even more distinct 
differences between AVN35 and PEG-NPs become apparent when the NPs are washed to 
remove the soft corona (Figure 2.3a, bottom, hard corona) (76).AVNs with 1–5 mol % PS 
containing membranes show a substantial decrease of Dhyd by ∼70–100 nm and an overall 
sharpening of the Dhyd distributions after removal of the soft corona. In contrast, the Dhyd 
distribution of the 35 nm core PEG-NPs before and after washing remains nearly 
unchanged. However, the behavior of AVN80 differs from that of AVN35. The average 
shift of the Dhyd distribution after corona (hard + soft) formation (Figure 2.3b, middle) is, 
around 50 nm, significantly smaller than for AVN35 (ΔDhyd ≈  100 nm). Also, the 
difference in the corona thickness between PEG-NP and the three types of AVN80 is less 
intensive, where the PEG-NP distribution shows only a slight broadening on the right side 
of the distribution. After removal of the soft corona through washing (Figure 2.3b, bottom) 
the average ΔDhyd values for AVN80 decrease by ∼25 nm, independent of the DOPS 
concentration. The smaller change in ΔDhyd associated with the removal of the soft corona 
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for AVN80 when compared with AVN35 indicates a thinner soft corona for the larger NP 
core. As in the case of the 35 nm NP core the effect of washing is the smallest for 80 nm 
PEG-NP. The ΔDhyd distribution still remains almost unchanged in this case. 
In general, we summarized in Figure 2.3c the average hydrodynamic diameters for AVN35 
and AVN80 without corona and with a hard corona. For both NP core sizes Dhyd increases 
 
 
 
Hydrodynamic diameter distribution from DLS intensity statistics for AVN35 (a) or AVN80 (b) for 
three different conditions: (i) no corona (top); (ii) hard + soft corona (middle); and (iii) hard 
corona (bottom). All DLS histograms are normalized. (c) Bar plots of average hydrodynamic 
diameters (Z-average size) for AVN35 (top) and AVN80 (bottom) without a corona (black) and 
with hard corona (red). The error bars are standard deviations from two independent 
measurements. (d) Structural models for corona formation around AVN35 and AVN80. Reprinted 
with permission from ref. 64. © 2016 American Chemical Society. 
 
Figure 2.3 Hydrodynamic diameter distribution from DLS intensity statistics 
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with increasing DOPS concentration (= increasing negative surface potential) in the 
assembled AVN membrane. The effect of the increasing negative charge on the hard 
corona of AVN35 and AVN80 is, however, smaller compared with the increase in size 
obtained for the corresponding PEG-NPs. 
However, one should not overlook that the agglomeration in colloidal NPs could also lead 
to the change of hydrodynamic size in addition to the corona formation. To rule out that 
the observed increases in the hydrodynamic diameter result from agglomeration rather than 
the corona formation, we monitored the plasmon resonances of the NPs, which are sensitive 
to NP clustering (77–79).We recorded UV–VIS spectra of the investigated NPs to 
 
 
UV-VIS spectra of AVN35 (a) and AVN80 (b) containing different DOPS concentrations under the 
conditions of i) no corona and iii) hard corona. (c) UV-VIS spectra of AVN35 and AVN80 containing 
different DOPS concentrations under the conditions of ii) soft corona. PEG-NPs were included as 
reference. 
Figure 2.4 UV-VIS spectra of AVN35 and AVN80 containing different DOPS concentrations 
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determine the agglomeration state of the NPs for all three conditions i–iii. The spectra 
(Figures 2.4) of all investigated AVNs show red-shifts in the range between 0 and 5 nm 
after corona formation; for the PEG-NPs the peak wavelength shifts between 4 and 7 nm. 
The absence of an asymmetric broadening of the plasmon resonance or the appearance of 
a new shoulder on the long-wavelength side in all cases except for the 80 nm PEG-NPs 
argues against a systematic agglomeration of the AVNs under the chosen experimental 
conditions. Instead, the magnitude of the observed systematic spectral shifts is consistent 
with an increase in the local refractive index around AVNs due to nonspecific protein 
adsorption (80, 81). Even in the case of the 80 nm PEG-NPs,  the very small broadening 
of the spectrum indicates only moderate levels of agglomeration. 
On the basis of the UV–VIS data, we attribute changes in Dhyd to the (de-)assembly of a 
corona for all three experimental conditions. Given the fact that the same DOPS 
concentration yields comparable zeta potential values for both AVN35 and AVN80, the 
pronounced differences in the thickness of the soft and hard corona observed 
in Figure 2.3 demonstrate that for NP, the core size has a profound impact on corona 
formation. The differences between AVN35and AVN80 imply curvature-induced changes 
in the interactions between AVNs and the proteins in their environment. The trends 
observed for the AVNs are consistent with previous studies (64) that demonstrated a larger 
increase in size after corona formation for smaller NPs. One possible model to account for 
the observed soft corona behaviors is outlined in Figure 2.3d. Size- or curvature-
dependent binding interactions between the proteins and the NP induce different structural 
configurations of the proteins in the inner coordination shell (= hard corona) of AVN35 and 
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AVN80. The size-dependent interactions result in the presentation of different groups or 
surfaces to the proteins of the ambient medium. According to this model, we assume that 
AVN80 with an intrinsically lower curvature contains a well-ordered inner-protein shell 
that saturates the binding sites of the attached proteins so that only a relatively well 
organized thin soft corona is formed. In contrast, for the smaller AVN35 the packing of the 
proteins in the inner layers is less perfect due to highly curved surface, creating a broad 
range of available binding sites for additional proteins from the immediate environment, 
resulting in an extensive soft corona protein network (82) associated with the NP core. 
By comparing the benchmark PEG-NPs with AVNs, the DLS data also show that the 
chemical nature of the NP surface affects the corona properties. PEG-NPs and AVNs with 
identical core size and comparable zeta potential values (Table 1) have different 
hydrodynamic diameters (compare PEG-NPs with 5 mol % DOPS containing AVN35 and 
AVN80 in Figure 2.3a and b).  
2.3 GM3-CD169 Mediated Targeting, in the Context of Corona Formation 
Naturally, one would ask, based on the corona formation characterized in the previous 
sections, if the protein adsorption onto the NPs interferes with the applicability of AVNs 
for lipid-guided targeting due to a potential loss in binding affinity. We tested this 
important question for GM3-mediated targeting of CD169. To that end, we again pre-
incubated GM3-presenting Au based AVN35 in 10% FBS containing DMEM at 37 °C 
for 24 h. After that, the NPs were collected by centrifugation, washed, and then added to 
CD169-expressing HeLa cells in FBS-containing medium. After 90 min of co-incubation 
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with an AVN35 preparation containing 1 or 5 mol % DOPS, we quantified the gold 
content in the cells by inductively coupled mass spectrometry (ICP-MS). As control we 
used AVN35 with 1 mol % DOPS but no GM3. Figure 2.5 summarizes the measured 
relative gold contents. The GM3-AVN preparation (3 mol % GM3+) with 1 mol % 
DOPS shows an approximately 6-fold higher binding than the control without GM3 
(GM3–). Interestingly, for the 5 mol % DOPS containing GM3-AVN sample the 
measured gold concentration drops and nearly approaches that of the GM3– control. The 
decreased binding observed in this case indicates an increased perturbation of GM3-
CD169 binding interactions due to a more efficient masking of the GM3 ligand by the 
thicker protein layer since the 5 mol % DOPS containing AVN35 particles have a higher 
negative surface charge, which results in a thicker hard corona (Figure 2.3c).  
As in complex biological fluids, many factors could lead to the cell-NPs interaction other 
than the GM3-CD169 binding. To further validate that the observed binding is GM3-
 
 
AVN35 binding to CD169 transfected HeLa quantified by ICP-MS for three different AVN 
configurations (from left to right): blank (GM3- / 1 mol% DOPS); GM3+ / 1 mol% DOPS; GM3+ 
/ 5 mol% DOPS; GM3+ / 1 mol% DOPS in the presence of an excess of GM3 containing 
liposomes. Reprinted with permission from ref. 64. © 2016 American Chemical Society. 
 
Figure 2.5 AVN35 binding to CD169 transfected HeLa quantified by ICP-MS 
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mediated, we incubated GM3-containing AVNs (1 mol % DOPS) with cells in the 
presence of an excess of GM3-containing liposomes. The GM3-containing liposomes are 
expected to outcompete AVN binding and achieve a strong reduction in the measured 
gold ion concentration (Figure 2.5). The successful competitive inhibition of AVN 
binding by GM3-presenting liposomes further favor the conclusion that the AVN binding 
is GM3-mediated. 
Another important question in the applications of AVNs is that in biological fluids, lipids 
derived from other cellular membranes are abundant and the possibility of lipid exchange 
and fusion in such an environment questions the stability of the AVN membrane. As 
GM3-presenting AVNs are intended for targeting CD169+ APCs, we evaluated the 
intracellular stability of AVNs with CD169+ macrophages and mature human dendritic 
cells (mDCs). We used AVN80 for these experiments, mainly because bright 80 nm gold 
NP core allows for an unambiguous detection of even individual AVNs under the dark-
field microscope. In parallel, we again included a fluorescent lipid marker (∼0.1 mol %, 
Liss-Rho-PE) in the AVN membrane (1 mol % DOPS), which facilitated a spatial 
mapping of the lipids in the APCs as a function of time through epifluorescence 
microscopy. In both CD169+ macrophages (Figure 2.6a) and mDCs (Figure 2.6b) we 
observed a strong correlation of lipid fluorescence and dark-field scattering signals from 
cell-associated AVNs for over 90 min, which is a characteristic time scale for NP uptake 
and processing in APCs. On the basis of these observations, we conclude that for the 
chosen membrane composition, which is rich in cholesterol (40 mol %), the AVNs retain 
a high degree of lipid membrane integrity in both CD169+ macrophages and mDCs. 
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APCs are well known for their “harsh” endocytotic conditions (acidic pH and high 
concentration of proteolytic enzymes) that facilitate efficient antigen presentation. The 
observation of a stable AVN membrane under these conditions highlights the robust 
nature of the AVNs. 
Even though both CD169+ macrophages and mDCs express the CD169 that is 
responsible for an efficient binding of GM3-AVNs, the fate of the AVNs’ spatial 
 
 
Optical colocalization of NP core darkfield signal and lipid label fluorescence signal confirms 
membrane stability of uptaken AVNs. a) Correlated color darkfield (top) and fluorescence 
(bottom) images of GM3-AVN80 in CD169+ macrophages recorded at the specified time points.  
b) Correlated color darkfield (top) and fluorescence (bottom) images of GM3-AVN80 in mDCs as 
function of time. Scale bars are 10μm. Reprinted with permission from ref. 64. © 2016 American 
Chemical Society. 
 
Figure 2.6 Optical colocalization of NP core darkfield signal and lipid label fluorescence signal 
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distribution pattern in these two APCs is very different. In CD169+ macrophages, AVNs 
are seemingly randomly distributed in a scattered pattern, while in mDCs the AVNs are 
segregated in large clusters. This GM3-specific segregation in mDCs has been observed 
before and was interpreted as a successful mimicry of GM3-mediated 
compartmentalization of the enveloped virus particles in deep peripheral membrane 
invaginations (41, 83).These differences can be exploited in the future for developing 
smart cell-specific delivery and drug release strategies. 
2.4 Targeting of CD169+ Cells in Vivo 
Finally, after demonstrating that GM3-AVNs could retain their binding selectivity for 
CD169-expressing APCs in vitro despite the formation of corona, we moved to the in 
vivo work and tested their applicability to target CD169-expressing APCs in secondary 
lymphoid tissues in mice. CD169+ macrophages and DCs are known to be enriched in 
the subcapsular sinus and perifollicular sinus (48, 84) , respectively. To assess whether 
GM3-AVNs could achieve a selective targeting to these cells in the peripheral regions of 
lymph nodes in the real biological body, in the presence of potential corona formation 
around the NP surface, we injected AVN80 (1 mol % DOPS) with (+) and without (−) 3 
mol % GM3 in the right and left hock, respectively, of living mice. We chose AVN80 
with 1 mol % DOPS, as these particles are shown could minimize corona formation in the 
previous in vitro studies. In each experiment 10 μL (2 × 1010 AVNs/mL in 1× PBS) of 
GM3-AVN80 colloid was injected. PBS injections (no AVNs) served as additional 
negative controls. We excised the popliteal lymph nodes and analyzed their gold content 
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via ICP-MS 1 and 4 h after injection. The measured gold amount for GM3+ and GM3– 
AVNs (2 repeats per condition) and controls are summarized in Figure 2.7. Both time 
points show a significant GM3-dependent enrichment in the lymph nodes, but the total 
GM3-AVN concentration in the lymph nodes increased by a factor of approximately 4 
between 1 and 4 h. 
Since CD169+ macrophages are known to be enriched in the subcapsular sinus in 
secondary lymphoid tissues in mice, a direct mapping of AVNs against these 
macrophages in the subcapsular sinus would demonstrate a successful targeting 
functionality of GM3 presenting AVNs. To that end, we investigated the spatial 
distribution of GM3-AVN80s (80 nm core, 1 mol % DOPS, ±3 mol % GM3) in lymph 
node sections prepared 1 h after AVN injection through dark-field microscopy. The areas 
embedded with signatures of scattering intensity with a golden metallic appearance in 
Figure 2.8a indicate gold NP enriched areas. However, to unambiguously identify the 
 
 
Gold concentration in excised popliteal lymph nodes 1 h (a) and 4 h (b) after hock injection of 
GM3-AVNs (GM3+) determined by ICP-MS. Left/Right refers to the flank of the animal from 
which the samples were taken. Controls include AVNs without GM3 (GM3-) and PBS. The data 
is from two independent experiments. Reprinted with permission from ref. 64. © 2016 American 
Chemical Society. 
 
Figure 2.7 Gold concentration in excised popliteal lymph nodes 
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position of the AVNs, we augmented this digital color image with a quantitative analysis 
based on hyperspectral wide-field imaging. As the elastic scattering spectrum of 
resonantly scattering Au NPs (the cores of AVNs) differs from that of the tissue, the 
intensity distribution recorded for each individual pixel in the field of view at different 
wavelengths provides a characteristic fingerprint to identify the AVNs (13).  In 
Figure 2.8b, a series of monochromatic wide-field images of the same tissue slice as 
in Figure 7a was collected at selected wavelengths between 500 and 640 nm in 20 nm 
(with a ±10 nm FWHM bandwidth) intervals. Figure 2.8c plots the wavelength-
dependent scattering intensities for selected pixels, which belong to either Au cores in the 
AVNs or the tissue background. Whereas the scattering intensity of the gold NP clusters 
demonstrates an almost linear increase as a function of wavelength while the tissue 
background is nearly flat. We could apply such distinct difference to generate the image 
processing algorithm to identify the locations of Au NPs. In Figure 2.8d, after applying a 
linear model based differentiation strategy, which discerns a gold NP signal from 
background by applying a threshold in the slope of the intensity versus wavelength 
relationship for each individual pixel, a binary image showing the locations of Au NPs 
was generated. The resulting binary image demonstrates a preferential accumulation of 
Au NPs in the periphery of the lymph node where the CD169+ APCs are located. To 
validate this, the peripheral localization of CD169+ macrophages is illustrated by 
fluorescence immunostaining in an independent lymph node section in Figure 2.8e. As 
control, the corresponding dark-field and binary images of GM3- AVNs contains no 
detectable gold NP signal and lacks any enrichment in the periphery of the lymph node. 
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In summary, the enrichment of GM3+ AVNs in lymph nodes and further in the CD169+ 
APC containing peripheral region of lymph nodes demonstrated a successful GM3-
mediated targeting of AVNs to CD169+ APCs in vivo. 
Inspired by the enveloped virus, the lipid membrane coated NPs, AVNs, combine the 
versatility of the self-assembled membrane to act as a platform for lipid-mediated 
targeting and to generate a protein-repellent passivation together with the superior 
materials properties of a central plasmonic NP core. The successful demonstration of 
GM3-mediated APC targeting in vivo, together with the obtained insight in corona 
 
 
 
Optical mapping of GM3-AVN80 in a lymph node section prepared 1 h after hock injection. a) 
Darkfield image of tissue section obtained for GM3-AVN80 (bottom). b) Monochromatic images 
from same field of view as in (a) but recorded every 20 nm between 500 nm to 640 nm. c) 
Intensity as function of wavelength for four marked positions in (a). d) Binary image generated 
through spectral filtering for the GM3+ AVNs. e) Immunostaining of CD169 from an 
independent lymph. f) Darkfield image of a lymph node section after hock injection of GM3- 
AVN controls. g) Binary image for (f) with the same algorithms applied in (d).  Scale bars are 100 
μm. Reprinted with permission from ref. 64. © 2016 American Chemical Society. 
 
 
Figure 2.8 Optical mapping of GM3-AVN80 in a lymph node section 
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formation around membrane-wrapped NPs and its dependence on NP size and charge, 
paves the path to a broader application of AVNs in immunotargeting approaches and the 
use of lipids as an NP targeting moiety in general. 
MATERIALS & METHODS 
Liposome and AVN Preparation 
A total amount of 1 μmole of lipid mix containing 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), cholesterol, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine 
(DOPS), GM3, and the fluorescence marker 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (liss-RHG-
PE) was dissolved in around 100uL chloroform in a 25ml round-bottom flask. The 
contributions from the individual lipids varied for different preparations as specified in 
the text. The solvent was then evaporated and the samples dried overnight in a vacuum 
rotary evaporator. 1 mL of 20 mM HEPES buffer (pH = 7.2) was then added to the lipid 
dry layer, forming a cloudy solution after vigorous agitation. The mixture was then 
probe-sonicated for 3-5 min under the argon protection until the solution became clear. 
The resulting liposome solution was stored at 4°C until further use. 1 mL of 80 nm citrate 
stabilized gold colloid solution (~1.0 × 1010 particles/mL), synthesized following the 
Turkevich method (66, 67) was pelleted via centrifugation at 2.4 krpm for 10 min. A 
volume of 0.5 mL of the prepared liposome solution was added to the gold NP pellet. The 
volume was increased to 1 mL with the same 20 mM HEPES buffer. A volume of 20 μL 
of 1 mg/mL 1-octadecanethiol solution in ethanol was then added to the mixture. The 
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mixed solution was incubated overnight on a rocker. After that, the AVNs were washed 
three times through centrifugation (2.4 krpm, 10 min) and resuspended in Milli-Q water. 
Finally, the AVN pellet was resuspended in 200 μL 20 mM HEPES buffer and ready to 
use. 
Dynamic light scattering and zeta potential measurements 
Measurements were performed on a Zetasizer Nano ZS90 (Malvern, Worcestershire, 
UK). For size measurements, AVNs were diluted with Milli-Q water to a final 
concentration of 1× 108 particles/mL. For zeta measurements, the AVN samples were 
further diluted to 1×107 particles/mL. 
UV-VIS spectroscopy  
Spectra of diluted AVN solutions (~1 × 108 particles/mL) of a total volume of around ~70 
μL in Milli-Q water(pH=7.0) were acquired in a quartz cuvette on an Agilent Cary 5000 
UV/VIS spectrometer. Milli-Q water was used for baseline correction. All spectra were 
normalized by dividing through the peak intensity. 
Cell-culture  
Primary monocyte-derived DCs were differentiated from CD14+ peripheral blood 
monocytes, and matured with LPS (100ng mL-1) for 2 days prior to use, as described 
previously. HeLa cells stably expressing CD169-mCherry fusion protein have been 
described previously.  
AVN Administration  
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In vitro experiments. For experiments with CD169-HeLa, CD169+ macrophages, and 
mDCs, AVNs were incubated with cells as specified for 15 – 90 min before the cells 
were washed by sequential centrifugation and resuspension with 1× PBS buffer three 
times. The cells were subsequently fixed with 4% paraformaldehyde and cytospun onto 
poly-L-lysine-treated glass coverslips. 
Hock vaccinations. A hock vaccination model was used to examine recruitment to 
draining lymph nodes (82). Briefly, mice were gently restrained and 10 μl of AVNs into 
the lateral aspect of the ankle, avoiding all major blood vessels. Mice were injected with 
2×108 particles in a total volume of 10ul with or without GM3 in both ankles. 10ul of 
PBS solution served as negative control. All animal procedures were carried out under 
BU IACUC protocol #14155 approved to Lee Wetzler. 
Lymph node preparation and sectioning 
One or four hours after hock vaccination, mice were euthanized using CO2. The draining 
popliteal lymph nodes (LNs) were removed and either directly frozen at -80˚C for ICP-
MS analysis or embedded in molds using Optimal Cutting Temperature (OCT) medium 
(Richard Allan Scientific, USA). Lymph nodes were flash frozen using dry ice and stored 
at -80˚C. Sectioning was performed on a Microm HM 550 (Microm International GmbH, 
Germany). 8 μm sections were obtained and placed on Colorfrost Plus slides 
(ThermoFisher, USA). Sections were stored at -80˚C until further processing. Sections 
were air dried for 15 minutes at room temperature, then fixed in acetone at -20˚C for 10 
minutes and afterwards dried for additional 10 minutes. Sections were re-hydrated in 
TBS buffer with 0.05% Tween-20 (TBS-T) then blocked for 20 minutes at room 
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temperature with TBS-T with 5% BSA. Sections were washed with TBS three times for 5 
minutes and mounted in SlowFade® Gold Antifade mounting medium containing DAPI 
(life technologies, USA). 
ICP-MS 
In vitro experiments. Binding studies were performed with the CD169 transfected HeLa 
cell line mentioned in the cell-culture section. After incubating the cell with GM3-
presenting AVNs (~1.0×108 particles/mL) for 90 min, the cells were washed, harvested 
and then transferred into centrifuge tubes. Excess particles and cells were separated by 3 
times centrifugation and subsequent resuspension at 1.5 krpm for 5 min. The cell 
concentration was then measured with a hemacytometer. Cell samples of known 
concentration were transferred into a 6-well dish and aqua regia was added to dissolve 
cells and contained gold NPs. The dish was then placed on top of a hot plate pre-set to 55 
°C for overnight to evaporate the aqua regia. The dried sample was re-dispersed in 2% 
HCl solution and measured, together with defined calibration standards in VG Plasma 
Quad ExCell ICP-MS to determine the gold concentration in the sample. 
In vivo experiments. Popliteal lymph nodes were excised from mice and placed into 
separate centrifuge tubes and stored at -80 °C until further use. Before ICP-MS analysis, 
each lymph node in the centrifuge tube was first dissolved in aqua regia at 80 °C for 1h 
and the resultant solution was then transferred into a 6-well dish. The dish was then 
placed on top of a hot plate pre-set to 55 °C for overnight to evaporate the aqua regia, On 
the next day, 2% HCl solution was used to re-disperse the dried samples before the 
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samples were measured together with calibration standards of known concentration in a 
VG Plasma Quad ExCell ICP-MS to determine the gold concentration in the sample. 
Image acquisition and data processing 
All optical imaging experiments were performed with an Olympus IX71 inverted 
microscope. Images were taken with a 10× or 60× oil objective with variable NA 
(NA=0.65–1.25). For darkfield imaging, the samples were illuminated with a 100W 
tungsten lamp through a high NA oil darkfield condenser (NA=1.2–1.4). Darkfield 
images were recorded with a Nikon D3100 SLR digital camera connected to the 
microscope through an eyepiece adaptor. Fluorescence imaging was performed under 
epi-illumination using appropriate filter sets. Images were recorded with an Andor Ixon+ 
electron multiplying charge coupled device detector. The NA of the collecting objective 
was adjusted for darkfield and fluorescence imaging to optimize signal to noise. The 
recorded images were further processed by ImageJ for coordinate alignment and overlay. 
Hyperspectral darkfield imaging was performed with a VariSpec Liquid Crystal Tunable 
Filter placed into the darkfield system to tune the excitation wavelength. The filter had a 
FWHM bandwidth of 10 nm and was scanned from 500nm to 640nm in steps of 20nm. 
Prior to a sample measurement a calibration based on the Averaged Optical Density 
(AOD) equalization method (82) was performed on a reference sample (empty glass 
substrate) to compensate for optical density variations stemming from the excitation light 
source and the optical system. An image from a lymph node sample was then acquired at 
each wavelength. The images were imported into Matlab where background corrections 
were performed and binary images were computed (see main text).  
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Chapter 3 MEMBRANE WRAPPED NANOPARTICLES FOR TARGETING 
VIRUS CONTAINING COMPARTMENTS: THE ANTAGONISTIC INTERPLAY 
BETWEEN GANGLIOSIDE GM3 AND PHOSPHATIDYLSERINE 
The presentation of Ganglioside GM3 molecule into the lipid membrane around the AVN 
endow the NPs with the functionality to target Siglec1 (CD169)-expressing myeloid 
dendritic cells and macrophages. Similarly, it has been suggested that HIV-1 also exploits 
GM3 to infect dendritic cells and macrophages in a glycoprotein gp120 independent 
fashion, in which GM3 binds to the sialic acid recognizing lectin CD169, which is 
expressed in macrophages and dendritic cells (85–87). More interestingly, the ganglioside 
receptor CD169 orchestrates the accumulation of exogenous virus particles in apparently 
intracellular compartments, so-called virus containing compartments (VCC) in 
macrophages and mDC (88, 89). With their unique structure and non-endolysosomal 
nature, VCC are deemed as an ideal reservoir for the virus to hide under the host’s 
immune system (55–57) and form a major obstacle for the eradication of HIV-1 with 
conventional combination antiretroviral therapy (cART), either due to long-term 
preservation of infectious virus particles, or decreased efficiency of anti-retrovirals to 
inhibit cell-associated HIV transmission (58, 59).In general, the inclusion of GM3 further 
extends the structural similarity to the practical infectivity resemblance of AVNs to the 
HIV-1.   
As specified previously, the addition of phosphatidylserine(PS) lipid to the membrane is 
to retain NP’s colloidal stability. However, the role of PS in the AVN is much more 
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complicated than just contributing to the colloidal stability. PS is also contained in the 
viral envelope and is a cofactor in the infection of monocytic cells by HIV-1(60).  By 
presenting PS on its surface, a virus particle imitates apoptotic cellular debris. In a 
process commonly referred to as viral apoptotic mimicry (62), HIV-1 and other viruses 
(61, 90), among them Ebola, are thought to enhance host cell binding, infection, and 
replication by parasitizing apoptotic debris clearance and anti-inflammation mechanisms.  
In the case of real HIV-1, both GM3 and PS are actually enriched in lipid rafts from 
which the virus preferentially buds (68).Consequently, both lipids are enriched in the 
viral envelope membrane and are available to interact with their respective receptors. 
However, it is currently unclear if and how PS and GM3 interact in leading the viral 
glycoprotein independent entry pathway that can either go through PS-mediated 
endocytosis/phagocytosis or collected in GM3-mediated VCC of macrophages.   
With the capability of presenting both GM3 and PS and further tuning their relative ratio 
in the membrane, AVN reserves its special position as a well-defined model to test the 
impact of the membrane composition, the interplay roles between GM3 and PS, and more 
specifically, in the viral infection. Throughout this chapter, we will again use the AVN 
model to elucidate the interplay of PS and GM3 in triggering VCC formation. We tune 
the ratio between GM3 and PS (GM3/PS) in the lipid membrane around AVN and 
demonstrate that VCC localization specifically requires GM3-CD169 interactions and 
that other structurally related gangliosides, such as GM1, fail to induce sequestration into 
VCC. We compare the intracellular fate of AVN with different GM3/PS ratios with HIV-
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1 virus like particles (HIV-VLP) and Ebola VLP. With the tuning of GM3/PS, we find 
that high GM3 amount in AVNs leads to the VCC invagination while conversely, high 
input of PS guide AVNs through endocytotic pathway. These findings suggest that 
membrane lipid composition, a crucial determinant of enveloped virus entry and 
trafficking, can be exploited to achieve intracellular targeting of NPs. 
3.1 Characterization of AVNs and cells: GM3/PS on AVNs & CD169 on THP-1 cells 
Again, The AVN design used in this chapter is outlined in Figure 3.1. Still, a membrane 
was self-assembled from known lipid components (1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), 
cholesterol, GM3) in pre-determined ratios around a central gold NP core. It is 
worthwhile mentioning that even though the structure of AVN is retained as in the 
chapter 2, the detailed membrane composition, especially the DOPS concentration, has 
been modified to explore the possibility of altering the intracellular fate of AVNs. 
 
Structural model of an AVN, which consists of a 90-nm Au NP core (yellow), an octadecanethiol 
inner membrane layer (orange), and a lipid membrane outer layer assembled from DPPC 
(green), DOPS (blue), GM3 (red), and cholesterol (not shown).  
Figure 3.1 AVN design and structure 
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Specifically, we focus in this study on the interplay of GM3 and PS and prepared AVN 
with five different GM3/PS mol% ratios within a physiological meaningful concentration 
range (91): 3/0, 3/2, 3/10, 0/3, and 0/10. The concentration range of different lipid species 
is also given in Figure 3.1.  
As the molecular concentration of PS, a negatively charged lipid molecule is primarily 
modulated here, the surface charge density of AVN could serve as a representative 
indicator to confirm a successful tuning of membrane composition. As shown in Figure 
3.2, the negative charge density of the AVN increases continuously as function of 
nominal PS concentration, implying a consistency between actual and expected PS 
concentration in the AVN lipid membrane. While the amount of GM3 stays the same, 
around 3% in all AVN groups except two extreme cases, where only high amount of PS 
is sustained (3% and 10%), we also measured the real amount of ganglioside inside the 
membrane. The inset in Figure 3.2 contains the relative ganglioside content (here GM1) 
 
 
 
The zeta potential of AVN with specified membrane composition shows a continuous decrease as 
function of PS concentration, while the ganglioside concentration shows no significant change. 
Figure 3.2 Zeta potential and relative ganglioside (here GM1) loading determined by ELISA   
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in AVN as determined by ELISA for different PS contents. The ELISA intensities show 
no significant differences between the AVN with different PS concentrations, suggesting 
that an increase in PS does not affect the ganglioside concentration in the membrane.   
Before setting out to systematically investigate the impact of the GM3/PS ratio on uptake 
and intracellular fate, it is worthwhile mentioning here that we chose CD169+ THP-1 
macrophages constitutively expressing CD169 (92)(differentiated into macrophages 
through phorbol myristate acetate (PMA) treatment) as a cell model in our studies. 
Macrophages express various PS receptors (93, 94) and CD169 expressing myeloid 
macrophages are known to be vectors of cis and trans HIV-1 infection (95). Importantly, 
sinus-lining CD169+ macrophages have been shown to play a central role in retrovirus 
trans-infection of lymphocytes in the lymph nodes (84). We then validated CD169 
expression in our THP-1 macrophage model through immunofluorescence labeling.  The 
representative images from confocal sectioning in Figure 3.3 shows that the surface-
 
Three selected confocal sections at increasing (1. - 3.) heights over the substrate and the complete 
3-dimensional confocal reconstruction show the surface distribution of CD169 in a THP-1/PMA 
macrophage. Note: to enhance CD169 visibility, basal membrane is shown pointing up in the 
reconstruction. 
Figure 3.3 CD169 is enriched in the basal plane on THP-1 macrophages 
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attached macrophages contain CD169 enriched in a rim around the basal membrane. The 
characterization of GM3/PS ratio on the AVN and CD169 expression on THP-1 cells 
paves the ground for further exploring the effect of GM3/PS ratio on AVN uptake. 
3.2 Effect of GM3/PS Ratio on AVN Intracellular Fate: Competitive Interplay 
between GM3 and PS 
Having in hand AVN with a rationally tunable membrane composition and knowing 
CD169 is enriched in the basal plane on THP-1 cells, we are ready to systematically 
investigate how GM3 and PS interact with each other in determining AVN intracellular 
fate.  
First, to characterize the effect of GM3/PS ratio on AVN uptake, we incubated the THP-1 
macrophages with AVN at a ratio of 1000:1 (particles: cell) for 45 min in serum free 
buffer then again we measured the cellular gold content by ICP-MS (Figure 3.4a). 
Interestingly in the ICP-MS data, GM3 without PS (3/0) or high PS concentration without 
GM3 (0/10) led to a much higher AVN uptake compared with the equivalent combination 
of both GM3 and PS (3/2 or 3/10). The co-existence of GM3 and PS in the lipid 
membrane around AVN results in an actual lowering uptake implies a possible 
competitive relationship between GM3 and PS. 
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To obtain additional insight into the mechanism of AVN uptake, we characterized the 
intracellular spatial distribution of AVN with different GM3/PS ratios and tested their 
colocalization with CD169 under the wide-field microscopy. Figure 3.4b shows 
representative images taken after 45 min of AVN incubation. For AVN with a GM3/PS 
ratio of 3/0 we frequently observed a phenotype, PH1, in which the AVN are confined to 
the CD169 enriched rim of the cell. However, if PS concentration in the membrane 
gradually ramps us, the colocalization of AVN and CD169 deteriorated and a second 
phenotype, PH2, containing AVN localized randomly scattered throughout the cytoplasm 
became more prominent with increasing PS content. Figure 3.4c summarizes the 
measured contribution of PH1 as function of GM3/PS ratio in the presence of 
 
 
a) Number of gold NP per cell as a function of GM3/PS ratio determined by ICP-MS. b) Wide-
field fluorescence images of AVN containing CD169+ THP-1 cells for different GM3/PS ratios. 
For GM3/PS = 3/0 AVN phenotype PH1 is prominent, which contains AVN confined to a narrow 
ring around the cell periphery where it colocalizes with CD169. With increasing PS content this 
colocalization decreases and phenotype PH2 with AVN distributed throughout the cytoplasm 
becomes prevalent. Scale bar: 5 μm. c) Relative contribution from PH1 for AVN with GM3/PS 
contents as specified in Poly-I treated cells after 45 min of incubation with AVN. 
Figure 3.4 Characterization of AVN binding and uptake in CD169+ THP-1 cells as function of 
GM3/PS ratio 
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polyinosinic acid (poly-I). Poly-I was added here to block PS-mediated AVN binding to 
scavenger/pattern-recognition receptors and facilitates a quantification of the effect that 
the GM3/PS ratio has on the CD169 templated peripheral enrichment of AVN, in other 
words, the PH1 pattern as it is dramatically distinct under the microscopy. Figure 3.4c 
shows clearly that the contribution of PH1 decreases with decreasing GM3/PS ratio. We 
conclude that AVN with low PS concentration (e.g. 3/0 AVN) are uptaken by CD169-
mediated cell-AVN interactions, whereas for higher PS concentrations (e.g. 3/10 AVN) 
uptake no longer exclusively depends on CD169 but is, instead, progressively dominated 
by PS receptors. 
The co-existence of two competing uptake pathways that culminate in distinct 
phenotypes PH1 and PH2, are possibly derived from the antagonism between GM3 and 
PS. However, the mechanisms behind such antagonistic behavior is unclear. One possible 
explanation for the experimentally observed behavior is that, as both GM3 and PS are 
negatively charged, there could be direct interactions between co-localized GM3 and PS 
that perturb receptor recognition and/or subsequent uptake. To validate the feasibility of 
an interaction between PS and GM3, we performed molecular dynamics (MD) 
simulations of the lipid distributions in a conventional lipid membrane bilayer (Figure 
3.5). We included coarse grained (CG) and all atom (AA) MD simulations here for 
completeness. Both computational approaches confirm interactions between GM3 and 
PS. The radial distribution functions and trajectory snapshots taken from the AA model 
reveal a spatial colocalization of GM3 and PS that is bridged by Na+ cations, whose 
concentration is enriched near lipid head group plane (Figure 3.5a and Figure 3.5b). In 
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CG simulations, a prominent peak in the GM3-PS radial distributions indicates strong co-
localization while the AA radial distributions in the inset shows comparatively modest 
nonspecific interactions. These differences in the exact peak positions and widths of the 
radial distribution functions of GM3 - PS and GM3 - Na+ in CG and AA MD simulations 
can possibly be due to the extended time scales and system sizes achieved in the coarse 
grained simulations, and the accurate description of the electrostatics in general, and 
more specifically the hydrogen bonds and aqueous solvation of the lipid head group in 
the AA model (42). Figure 3.5b displays the GM-PS co-localization with the Na+ ions in 
the background, evident in the final configuration of the coarse grain and all atom 
simulations. 
 
 
a). (Main) Radial distribution functions (g(r)) of PO4 bead of PS head groups (green), PO4 bead 
of DPPC, and ROH bead of cholesterol head groups (black), and Na+ (blue), with GM1 bead of 
GM3, in coarse grained (CG) simulations. (Inset) g(r) of P atoms of PS head groups (green), P 
atoms of DPPC and O3 atoms of Cholesterol head groups (black), and Na+ (blue), with heavy 
atoms of GM3 carbohydrate groups, in all atom (AA) simulations. b) Side view of the entire 
membrane, top view of the membrane head group plane (indicated by the dotted square) of 3/10 
AVN. A close-up view of the final configuration of the 1.2 µs AA system is included as inset. 
Membrane components are rendered in space filled spherical representation with the color coding, 
GM3: purple, DOPS: green, DPPC and cholesterol: grey, Na+: blue, Cl-: yellow, water (TIP3P): 
cyan. 
Figure 3.5 Molecular Simulation of interaction between GM3 and PS 
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Based on the experimental observations and theoretical simulations, we propose that Na+ 
mediated co-localization of the both negatively charged GM3 and PS head groups, and 
such colocalization interferes with the recognition of the lipids through their cellular 
receptors and effectively reduces the avidity of AVN containing both GM3 and PS. 
It could be observed from experiments that PH1 majorly corresponds to 3/0 AVN while 
PH2 is primarily associated with 3/10 AVN. To further map out the exact spatial 
distributions of 3/0 and 3/10 AVNs, we applied focused ion beam scanning electron 
microscopy (FIB-SEM) to characterize the NP distribution in these phenotypes with 
higher spatial resolution than is possible with optical microscopy, in which ion beam 
milling was used to gradually remove cellular material and facilitate the acquisition of 
SEM images at different cell depths. Figure 3.6a shows SEM images for macrophages 
incubated with either 3/0 AVN or 3/10 AVN for 45 min after different milling times 
between 5s and 155s. For 3/0 AVN (GM3-mediated uptake, PH1), NP clusters are 
detectable only during the first 95 s of ion milling, whereas in the case of 3/10 AVN (PS-
mediated uptake, PH2) individual NP are detected nearly at all time points. We could 
conclude that while 3/10 AVN remain to a large degree monomeric and are distributed 
throughout the cytoplasm, 3/0 AVN are preferentially collected as clusters close to the 
basal plasma membrane, in the vicinity of CD169 receptors on THP-1 cells (Figure 3.3). 
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The different NP clustering levels for PH1 and PH2 are further corroborated by spectral 
shifts in the plasmon resonance of the gold NP labels. The resonance wavelength of gold 
NP depends on their clustering (96, 97) and, thus, provides information about their spatial 
compartmentalization during trafficking. In Figure 3.6b, we plot the peak position 
(wavelength) of the dark-field spectra of certain discrete AVN recorded after 5 and 45 
min. A characteristic spectral red-shift and broadening for 3/0 was observed, but not for 
 
 
a) FIB-SEM images recorded 45 min after AVN addition (top row: 3/0 AVN; bottom row: 3/10 
AVN). The images show the same CD169+ THP-1 cells at different stages of excavation through 
focused ion beam milling (specified as depth of milling). Scale bars: 2 μm. b) Scatterplot of 
normalized intensity as function of fitted peak wavelength for six randomly selected 3/0 and 3/10 
AVN emitters in CD169+ THP-1 cells at 5 and 45 min post AVN exposure.  
Figure 3.6 Intracellular fates and distributions differ for 3/0 and 3/10 AVN 
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3/10 AVN. The red-shift observed for 3/0 AVN again signifies a collection of AVN in 
sub-diffraction-limit clusters at the cell periphery, whereas in the case of 3/10 AVN, the 
endocytosed NP remain essentially monomeric over the investigated time range of 45 
min. 
3.3 Selective Targeting:  the Antagonism between GM3 and PS Leads to Targeting 
VCC 
So far, all the characterizations on the intracellular fate of AVNs have been limited at the 
time of 45min upon incubation. To probe the final intracellular fate of 3/0 and 3/10 AVN, 
we mapped their spatial distribution after 16h. Conventionally, NPs are sequestered into 
lysosomal compartments, we thus first performed immunolabeling to detect the 
intracellular distribution of the lysosomal associated membrane protein 1(LAMP-1) in 
order to check for putative co-localization of AVN with lysosomes. In Figure 3.7, we 
show confocal sections of 3/0 (top panel) and 3/10 (bottom panel) AVN together with the 
 
Confocal section of CD169+ THP-1 cells incubated with 3/0 AVN (top) and 3/10 AVN (bottom) for 
16 h and immunolabeled for LAMP-1. 3/0 AVN show poor colocalization with LAMP-1, while the 
majority of 3/10 AVN are localized in LAMP-1 positive areas in the cytoplasm. Scale bars: 5 μm. 
For the entire cell population the colocalization rates between AVN and LAMP-1 were 23% in the 
case of 3/0 and 64% for 3/10. 
 
Figure 3.7 Confocal section of CD169+ THP-1 cells stained with LAMP-1 
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immunolabeling of LAMP-1. The confocal scans reveal that after 16 h, the 3/0 AVN are 
no longer exclusively located at the cell periphery but can also be found in the cell 
interior. However, the 3/0 AVN colocalize poorly with the lysosome, with a 
colocalization rate around 23 %. While for 3/10 AVN, around 64% of the endocytosed 
particles are located in cellular compartments that co-stain with LAMP-1. We thus 
conclude that although the 3/0 AVN eventually detach from the cell periphery, they do 
 
 
Left column: Confocal sections of CD169+ THP-1 cells stained for CD9 and containing 3/0 AVN 
(top row) and 3/10 AVN (bottom row). For the entire cell population the colocalization rates for 
AVN and CD9 were 72% in the case of 3/0 and 8% for 3/10. Right column: Confocal sections 
stained for tetherin and containing 3/0 AVN (top row) and 3/10 AVN (bottom row). Population 
colocalization rates for AVN and tetherin were 73% in the case of 3/0 and 16% for 3/10. Scale bars: 
5 μm. 
Figure 3.8 3/0 AVN but not 3/10 AVN colocalize with VCC markers 
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not enter a lysosomal degradation pathway. In contrast, 3/10 AVN still follow a 
lysosomal pathway to enter the cell.  
The pronounced differences in the spatiotemporal distribution and intracellular fate 
between 3/0 and 3/10 AVN highlights that 3/0 AVN are internalized through a unique 
pathway that avoids lysosomal compartments. 
It has recently been demonstrated that CD169 mediates the formation of VCC (89) , 
which are non-endolysosomal intracellular compartments in macrophages. Therefore, we 
speculated that 3/0 AVN end up in the VCC to account for their non-endolysomal 
intracellular fate. To test this hypothesis, we systematically probed for optical 
colocalization between 3/0 AVN and VCC markers, such as tetherin or the tetraspanin, 
CD9 under the confocal microscopy. In Figure 3.8, we inspect the co-localization 
between CD9 and tetherin, and 3/0 and 3/10 AVN, respectively, by confocal microscopy. 
All images were acquired 16 h after AVN addition. Both CD9 and tetherin colocalize 
with 3/0 AVN but not 3/10 AVN, with colocalization rates of 72% and 8% (CD9) and 
73% and 16% (tetherin) for 3/0 and 3/10 groups, respectively. The confocal images first 
confirm the trend from Figure 3.7 that although some 3/0 AVN are still localized to the 
plasma membrane, a significant fraction of AVN have translocated into the cell interior. 
Most importantly, the well-established colocalization between 3/0 AVN and tetherin and 
CD9 reveal that the 3/0 AVN containing compartments located at the membrane or in the 
cell interior identify as VCC (89). 
In recent findings, GM3 presenting exogenous HIV-1 Gag virus-like particles (HIV-
VLP) colocalize with HIV-1 in the VCC of infected monocyte derived macrophages 
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(MDM) (89). We, therefore, tested whether GM3-presenting AVN can successfully 
mimic the behavior of HIV-1 Gag VLP in term of ending up in the VCC. To that end, we 
first incubated CD169+ THP-1 cells with HIV-1 Gag VLP for 1 h and then added 3/0 
AVN to challenge the cells for another 1 h. After that, extra VLP and AVN were washed 
away and the cells were imaged after another 14 h of co-incubation. In Figure 3.9, we 
inspect the co-localization between AVN and HIV-VLP in a representative confocal 
section. The images reveal an almost indistinguishable spatial distribution between HIV-
VLP and AVN after they enter CD169+ THP-1 cells. From the obvious co-localization 
between HIV-1 VLP and AVN in this confocal section, one could not only conclude that 
3/0 AVN enter CD169+ THP-1 cells through the VCC pathway but also legitimately 
infer that AVN and VLP trigger identical cellular uptake mechanisms.  
For completeness, we then investigated whether 3/10 AVN that - due to their high PS 
content - enter the endolysosomal uptake pathway colocalize with virus particles that are 
known to utilize PS-mediated binding to host cells. To that end, we chose Ebola VLP as 
 
 
AVN and VLP show a high degree of spatial colocalization in CD169+ THP-1 cells after 16h 
incubation. Two independent cells are shown here. 
Figure 3.9 3/0 GM3 AVN and HIV-1 Gag VLP colocalize in VCC 
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test case (98). In Figure 3.10, we map the spatial distribution of 3/10 AVN, Ebola VLP, 
lysosome marker (LAMP-1), and VCC marker (CD9) after 16 h of co-incubation. The 
figure shows an unambiguous colocalization between 3/10 AVN and Ebola VLP. Both 
3/10 AVN and Ebola VLP colocalize with LAMP-1 but not CD9. Such colocalization 
patterns confirm that AVN with high PS content and Ebola VLP are both collected in the 
lysosome.  
The experiments of AVN together with VLP show that by variation of the GM3/PS 
content in the AVN membrane intracellular trafficking and destination of either HIV-
VLP or Ebola VLP can be mimicked. The difference in the intracellular fate depends 
only on the chosen GM3/PS ratio. For completeness, we found that HIV-1 VLP co-
incubated with 3/10 AVN or Ebola VLP with 3/0 AVN did not show significant 
colocalizations between AVN and VLP. 
 
 
Co-localization between Ebola-VLP, 3/10 AVN, lysosome marker LAMP-1 (left) and VCC 
marker CD9 (right).  Ebola VLP and 3/10 AVN colocalize with each other and LAMP-1 but not 
CD9, confirming that PS-AVN and Ebola VLP are sequestered into lysosomes, rather than the 
VCC. Scale bars: 5 μm. 
Figure 3.10 3/10 AVN and Ebola VLP are collected in lysosomes 
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3.4 Uniqueness of GM3 AVN Model: GM3 and Core Stiffness Dependent VCC 
Pathway 
So far, our minimalistic virus model that comprises only four compounds, 
phosphatidylcholine (PC), PS, GM3 and cholesterol, provides experimental evidence that 
the formation of VCC is GM3-CD169 recognition mediated. However, one should not 
overlook that monotetrahexosylganglioside (GM1), which is structurally related to GM3, 
also contains a terminal branched sialic acid residue that could bind CD169. The sugar 
unit in the head group is, however, two units longer for GM1 than for GM3. We then set 
out to investigate if GM1 AVN could similarly contribute to the formation of VCC. 
Despite GM1’s ability to bind to CD169, AVN with a similar membrane containing 3 
mol% GM1 and 0 mol% PS failed to induce VCC. Instead, GM1 presenting AVN were 
collected in the lysosome after 16h, and the GM1 containing AVN show no overlap with 
the VCC markers CD9 and tetherin (Figure 3.11). Through the GM1 experiments, we 
conclude that VCC formation specifically requires GM3-mediated binding to CD169. 
The dependence of the AVN intracellular fate on the exact molecular structure of the 
sialic acid containing head group underlines the sensitivity of the recognition process and 
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corroborates our hypothesis that Na+-mediated PS-GM3 contacts perturb this 
mechanism. 
Another caveat is that our analysis has been focused entirely on elucidating how the AVN 
membrane composition impacts AVN-cell interactions and switch between VCC and 
 
 
Confocal section of CD169+ THP-1 cells exposed to 3 mol% GM1 containing AVN (no PS) and 
immunostained for LAMP-1 (top row), CD-9 (middle row), and tetherin (bottom row). All images 
were acquired 16h after AVN exposure. Scale bars: 5 μm.  
Figure 3.11 GM1-CD169 interactions do not induce VCC formation 
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endosomal pathways, ignored the role of the NP core in the AVN design. However, other 
aspects of the AVN can also play an important role. Of particular interest is the role of 
the core, as the stiffness of the virus particle has been shown to affect HIV infectivity in 
different stages (99, 100).  To that end, we exploited the AVN synthesis precursor, 
liposomes with the same composition to probe the role of core. Intriguingly in our 
experiments, conventional liposomes without NP core but identical nominal membrane 
composition failed to induce VCC formation. As shown in Figure 3.12, neither 3/0 nor 
3/10 liposomes co-localize with tetherin. Instead, both enter an endolysosomal uptake 
pathway as indicated by their colocalization with LAMP-1. The difference between the 
 
 
Left column: Confocal section containing 3/0 (top) and 3/10 (bottom) liposomes and 
immunolabeled for tetherin. The image was acquired 16 h after AVN addition. Right column: 
Confocal section containing 3/0 (top) and 3/10 (bottom) liposomes and immunolabeled for 
LAMP-1 under otherwise identical conditions. Scale bars: 5 μm. 
Figure 3.12 3/0 and 3/10 liposomes enter an endolysosomal pathway 
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3/0 liposome and AVN implies that the GM3 and CD169 recognition alone is insufficient 
to induce VCC formation, but that the NP core itself or its function in presenting and 
organizing the lipids on the NP surface also plays a role in determining the intracellular 
fate.  
In summary, our findings of localization of membrane-wrapped NP within VCC was 
specific to GM3-mediated binding and required a solid NP core, indicating that 
sequestration into VC has requirements beyond ligand (GM3) – receptor (CD169) 
recognition that are related to physical properties of the NP core, such as its stiffness. 
Since VCC are HIV assembly and accumulation sites, our GM3-presenting AVN define a 
rational strategy for targeting a putative viral reservoir in macrophages and provides new 
opportunities for addressing viral persistence. 
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MATERIALS & METHODS 
Ganglioside GM1 ELISA 
Relative GM1 loadings on AVN were quantified through a tetramethylbenzidine based 
sandwich ELISA kit in a polylysine coated 96 well-plate. The individual wells were 
incubated with AVN for 1h. After that the AVN solution was retrieved from the wells. 
We determined the AVN concentration before and after loading of the wells and the 
difference in the number of AVN was assumed to be bound to the wells. After thoroughly 
washing each well with washing buffer (Thermo Fisher Scientific), 200 L of a 100 
ng/ml rabbit polyclonal anti-GM1 antibody (abcam) solution was incubated in the wells 
for 2h at room temperature. After removal of excess antibodies through 3 times washing, 
200 L of a 10 ng/mL goat anti-rabbit IgG HRP conjugated antibody (abcam) solution 
was added into each well and incubated for 1 h. After washing for 3 times, 0.5 mM TMB 
solution was added into each well and incubated for 30 min before a stop solution was 
added. The plate was then read under 450 nm and also 550 nm to background correction. 
Three independent ELISA runs were performed and all raw data was imported into 
OriginLab for processing to correct for the amount of AVNs retained in each well and 
further for a statistical significance analysis (t-test) at the 95% level. 
Cell-culture 
THP1/CD169 cells  (CD169+ THP-1) have been described previously (55). CD169+ 
THP-1 cells were cultured in 10% fetal bovine serum, 1% penicillin–streptomycin, 2% 
G418 in RPMI-1640 medium (Gibco Cell Culture, Thermo Fisher Scientific, USA). 
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CD169+ THP-1 cells were differentiated into macrophages by incubation with 1 nM 
phorbol myristate acetate (PMA, Sigma) for 48hrs.  
VLP Generation. HIV Gag-eGFP VLPs and Ebola eGFP-VP40 VLPs were produced via 
transfection of HEK293T cells, as described previously (37).  
AVN Administration  
AVN with a pre-determined GM3/PS ratio were incubated with CD169+ THP-1 cells at a 
concentration of 1x107/mL (1000 AVN/cell) for 5 or 45 min, as specified, in FBS free 
RPMI-1640 medium three times. The unbound AVN were then removed and the cells 
were washed and fixed for inspection in the optical microscope. In some experiments the 
cells were subsequently lysed to determine the average gold content per cell by ICP-MS. 
For the 16 h experiment, cells were washed with warm RPMI-1640 medium after 45 min 
of incubation with AVN and then maintained in the CO2 incubator for another ~16 h. 
The cells were subsequently fixed with 4% paraformaldehyde for 12 min and then 
washed with 1X PBS buffer prior to image acquisition. 
ICP-MS 
Cells were washed 3 times with warm 1X PBS buffer and harvested using a cell 
dissociation buffer (Gibco, Thermo Fisher Scientific, USA). After that, the cells were 
transferred into centrifuge tubes. Excess particles and cells were separated by 3 times 
centrifugation at 1.6 krpm for 5 min and subsequent resuspension in 1X PBS. The cell 
concentration was then measured with a flow cytometer. Cell samples of known 
concentration were transferred into a 12-well dish and fresh aqua regia was added into the 
57 
 
wells to dissolve cells and the contained gold NP. The dish was then placed on top of a 
hot plate pre-set to 55 °C for overnight to evaporate the aqua regia. The dried sample was 
re-dispersed in 2% HCl solution and measured, together with defined calibration 
standards in VG Plasma Quad ExCell ICP-MS to determine the gold concentration in the 
sample. 
FIB-SEM 
Cells intended for FIB-SEM sectioning were first cultured on a 0.01 vol% polylysine pre-
treated 1cm × 1cm Si chip and exposed to AVN as described above. Cells were then 
fixed in 4% paraformaldehyde and 1% glutaraldehyde in 0.1M sodium cacodylate buffer 
(pH 7.2) for 15 min at room temperature. After that the samples were incubated with 1% 
osmium tetroxide in distilled water for 30min. Subsequently, samples were washed with 
distilled water and then dried with 50%, 75%, 95% and 100% ethanol solution and finally 
placed in Hexamethyldisilazane (HMDS) for overnight. Samples were imaged first using 
a Zeiss Supra 40VP SEM at 2.0 kV and a working distance of 10 mm. The samples were 
subsequently milled with an FEI Quanta 3D FIB instrument using a voltage of 30.0 kV 
and a current of 0.5 nA for the specified time durations.  
Image Acquisition and Data Processing 
All optical imaging experiments were performed with either an Olympus IX71 inverted 
widefield microscope or an Olympus FV1000 scanning confocal microscope. For images 
taken on the widefield microscopes, a 60× oil objective with variable numerical aperture 
(NA=0.65–1.25) was used. For darkfield imaging, the samples were illuminated with a 
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100W tungsten lamp through a high NA oil darkfield condenser (NA=1.2–1.4). Darkfield 
images were recorded with a Nikon D3100 SLR digital camera connected to the 
microscope through an eyepiece adaptor. Fluorescence imaging was performed under 
epi-illumination using appropriate filter sets with mercury lamp. Images were recorded 
with an Andor Ixon+ electron multiplying charge coupled device detector. For images 
taken on the confocal microscope, a series of 10×, 20×, 40× and 60× (water) objectives 
were used to localize the field of interest. Confocal fluorescence images were recorded 
using different excitation wavelengths (433, 488, 633 nm) as needed for the applied dyes. 
All recorded images by widefield and confocal microscopes were further processed by 
ImageJ for coordinate alignment, overlay and generating pseudo-colors. 
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Chapter 4 THERAPEUTIC TARGETING AND DELIVERY TOWARDS 
LYMPHATIC SYSTEM: MESO-POROUS SILICA BASED LIPID WRAPPED 
NANOPARTICLES 
Due to their advantageous photo-physical properties and ease of fabrication and surface 
modification, gold nano-particles (Au NPs) are widely exploited in the bio-engineering 
applications as a new generation of bio-physical tools. In those applications, Au NPs are 
preferentially taken as tagging probes in the imaging context due to Au NP’s large 
scattering cross-section and extreme photophysical stability (8). Such brightness and 
photostability make plasmonic NPs easily stand out against the background. However, 
with a relatively smooth crystalized surface, Au NPs generally do not serve as a good 
matrix to carry therapeutic agents to fulfill a target delivery purpose. In contrast to Au 
NPs, meso-porous silica nanoparticles (MSNs) are promising materials for delivery 
purposes. MSN possess a unique structure with a tunable pore and particle size, resulting 
in a high area/volume ratio which can be easily loaded with therapeutic agents (101). 
More importantly, silica is bio-compatible and is classified as “Generally Recognized as 
Safe” (GRAS) by the FDA and is widely used in cosmetics and as a food-additive, which 
paves way for its applications in the biological system.  
Even though the MSNs’ porous structure allows for a high loading capacity of 
therapeutic agents but the cargo could still be absorbed to the MSN surface, in which case 
a sealing of MSN is necessary to improve loading’s pharmacodynamical characteristics. 
To that end, the passivation of MSN by the lipid membrane again plays a role here as the 
membrane could serve as the gatekeeper for a controlled release of loading inside a 
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biological system. Previously, the addition of GM3 into the membrane allowed for a 
selective targeting of AVN towards CD169+ APCs inside mouse lymphatic system and 
endowed the AVN physico-chemical characteristics that facilitated entry into APCs 
through endosome independent VCC pathway, mimicking HIV-1 particles. The 
combination of MSN with GM3 presented lipid membrane could achieve the goal of 
selectively targeting HIV-1 reservoir sites in secondary lymphatic tissues. 
Current approach for an efficient treatment of HIV-1 inside human body is the usage of 
anti-retrovirals (ARVs) to target tissue reservoirs of HIV-1 (102). One of the ARVs that 
has been approved by the FDA with higher potency, longer half-life and reduced side-
effect profile is Rilpivirine (RPV) (103), a second generation of non-nucleoside reverse 
transcriptase inhibitor (NNRTI). In this chapter, we will mainly use RPV as our primary 
therapeutic agent for the inhibition of HIV-1. We first set out to validate MSN based 
GM3 AVN’s ability to target secondary lymphatic tissues in mice through Magnetic 
Resonance Imaging (MRI) by loading MRI sensitive gadolinium compounds in GM3-
MSN.  We next compared the ability of MSN based AVN/RPV to soluble RPV or 
commercially available long acting RPV (LA-RPV) compound for inhibiting HIV-1 
replication. We find that RPV incorporated within MSN based AVN  is about 1000 times 
efficient than pure RPV or LA-RPV in inhibiting HIV-1 infection in vitro. Finally, 
through a systematic design, we explore the mechanism that mediates such high anti-viral 
potency, and hypothesize that it is potentially due to similar hydrophobic characteristics 
of MSN and RPV. 
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4.1 MSN Based AVN Design, Synthesis and Characterization 
Similarly, the membrane was self-assembled from known lipid components (1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phospho-L-
serine (DOPS), cholesterol, GM3) in pre-determined ratios from liposomes. From 
established experiments, we found a specific membrane composition with 56 mol% 
DPPC, 40 mol% cholesterol, 3 mol% GM3 and 1 mol% DOPS could repel the corona 
formation at the highest degree while still sustaining AVN’s colloidal stability without 
losing its targeting functionality towards CD169+ myeloid macrophages and dendritic  
 
 
a). Co-localization between lipid membrane and MSN NP core. Left: darkfield image of the MSN 
NP core; Middle: Fluorescence image of lipid membrane; Right: Composite image of darkfield 
and fluorescence. Scale bar: 5 μm. b). TEM and SEM images of the MSN core. Left: TEM (scale 
bar:50nm); Right: SEM, scale bar:200nm. 
Figure 4.1 MSN based AVN colocalization and MSN structure.   
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cells. Throughout this chapter, the membrane composition will follow such specific 
recipe unless otherwise specified. 
Previously to successfully wrap the membrane around the Au NP core, octadecanethiol 
was added into the liposome-Au NPs mixture so that octadecanethiol binds readily to the 
Au core surface and establishes a hydrophobic surface onto which lipids from co-
incubated liposomes can spread, anchor and further form lipid membrane. In the case of 
MSN based AVN, a gold NP core was replaced with a MSN, which could already render 
a relatively hydrophobic surface (104), there is no need to add octadecanethiol here 
anymore. However, as steps are modified here, we still validated the existence of lipid 
membrane around the MSN core. In Figure 4.1a, the almost 100% co-localization of 
fluorescence with dark-field signals again confirms a successful wrapping of membrane 
around the MSN core. For completeness, we also show the transmission electron 
microscope (TEM) and scanning electron microscope (SEM) images of MSN core in 
Figure 4.1b. In the TEM and SEM images, a relatively curved(?) and rough surface and 
 
 
Colocalization of dark-field MSN cores (left) and loaded RHG B fluorescent molecules (right). 
Scale bar: 5μm 
Figure 4.2 Colocalization of loading test. 
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small pores could be observed, which essentially serve as reservoirs to shelter the 
loadings inside.  
To further investigate MSN’s loading capacity before running bio-assays, we first loaded 
Rhodamine B (RHG B), a water soluble fluorescent molecule into the MSN without the 
membrane wrapping. RHG B molecule is chosen here primarily as a marker to 
characterize small pores’ loading functionality on the surface of MSNs. We then applied 
the same approach of colocalization to test if RHG B has been successfully incorporated 
into the MSN.  In Figure 4.2, we again observed almost 100% colocalization of 
fluorescence signal from the RHG B with dark-field signals implying that MSN can serve 
as a spacious carrier for loading bio-function molecules. 
4.2 MSN Based AVNs (MS-AVNs) as a Novel MRI Agent Carrier: in Vivo Studies 
In previous two chapters, we have successfully demonstrated that GM3 Au NPs could 
target CD169+ myeloid macrophages and dendritic cells both in vitro and in vivo. 
Through those pioneering work, we established the mimicry between GM3 Au NPs and 
HIV-1 in terms of their similar fate of ending up in the VCCs of human macrophages. 
After exchanging the Au core with the MSN core, it is of essential interest to investigate 
if those GM3 MS-AVNs could still target CD169+ cells as Au GM3 AVNs. As extensive 
in vitro studies had been conducted previously, we will mainly focus on the in vivo work 
in this section.  Instead of the experiments with excision of lymph nodes from mouse to 
analyze GM3+ Au AVN amount against GM3- Au AVN in chapter 2, we directly 
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analyze the location and amount of GM3+ MSN based AVN against the GM3- group 
through the MRI technique.  
In the application of MRI, contrast agents are commonly used to improve the visibility of 
internal body structures. The most commonly used compounds for contrast enhancement 
are gadolinium-based (105). The purpose of such MRI contrast agents is to shorten the 
relaxation times of nuclei within body. In a typical MRI scan, sections of the body are 
exposed to a very strong magnetic field causing primarily the hydrogen nuclei ("spins") 
of water in tissues to be polarized in the direction of the magnetic field. The magnitude of 
the spin polarization detected by the instrument is used to form the MR images but 
decays with a characteristic time constant known as the T1 relaxation time. Water protons 
in different tissues have different T1 values, which is one of the main sources of contrast 
in MR images. A contrast agent usually changes the value of T1 of nearby water protons 
thereby altering the contrast in the image. In our experiments, we use gadolinium 
bromide (GdBr3) as the primary contrast agent. We load the GdBr3 into the MSN core 
simply by incubating MSNs in the GdBr3 solution for overnight. 
Before running the in vivo experiments, we first test such AVN associated gadolinium 
based contrast agents assay in a simulated in vivo environment. Here we use 1% agarose 
gel to simulate the background tissues and immerse the MS-AVNs loaded with GdBr3 in 
a concentration controllable fashion: we serially diluted the stock solution of GdBr3 
loaded MSN AVNs (Gd-MS-AVNs) into the 1% agarose into different wells of the 96-
well dish and place the whole dish under the MRI scan. In Figure 4.3, the MR images of 
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those wells are displayed as a function of the concentration of Gd-MS-AVNs: the first 
number corresponds to the volume (in µl) of original AVN solution (1 × 1010 
particles/ml) while the second is associated with the volume (in µl) of the diluent, which 
is the 1% agarose here. As the concentration of Gd-MS-AVNs gradually increases from 
about 0.3 × 108 particles/ml to about 0.6 × 1010 particles/ml, the MRI intensities of 
corresponding wells are strengthened. Figure 4.3 also displays the quantification of 
average intensities of each group. A concentration dependent increase in MR intensity 
could also be observed.  
With the rationally designed MS-AVNs as a carrier for contrast agent validated through 
simulated in vivo work in the MRI application, we then characterized those GM3 Gd-MS-
AVNs performance in vivo. Similar to the comparison between GM3+ and GM3- AVNs 
performed in chapter 2, we again investigated if the presentation of GM3 on the surface 
of Gd-MS-AVNs plays a role or not in affecting the accumulation and retention of MS-
AVNs inside mouse lymphatic system. We injected Gd-MS-AVNs with (+) and without 
 
 
Left: MRI sectioning of wells. Right: Corresponding quantification of intensities in the left 
images. The first number corresponds to the volume (in µl) of original AVN solution while the 
second is associated with the volume (in µl) of the agarose gel.  
Figure 4.3 MRI scan of Gd-MS-AVNs with different concentrations in the agarose gel. 
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(−) 3 mol % GM3 in the right and left hock, respectively, of living mice. In each 
experiment 10 μL (4 × 108 AVNs/mL in 1× PBS) of Gd-MS-AVNs was injected. PBS 
injections (no AVNs) served as additional negative controls. After 4hrs upon injection, 
mice were sacrificed using CO2 and subsequently analyzed by MRI. In Figure 4.4, we 
show images from MRI sectioning for GM3+, GM3- and negative control (1X PBS) 
groups. As displayed in the left mouse in Figure 4.4a, Gd-MS-AVNs without GM3 
(control) were injected in the left hock and GM3+ Gd-MS-AVNs in the right hock, 
noting that the enrichment of GM3+ Gd-MS-AVNs in the right compared with GM3- 
control in the left, indicated by relative greyscale intensities in the images.  In the left 
mouse, the right hock was injected with 1X PBS buffer only while the right hock was 
again injected with GM3+ Gd-MS-AVNs, a more drastic contrast could be observed from 
the right side (GM3+) compared with the left side. Figure 4.4b provides another 
sectioning of the same mice. For completeness, the MRI scan of the mice without any 
treatments is also shown in Figure 4.4c, which again points out the functionality of Gd-
MS-AVNs in improving the contrast of MRI scanning.  
The combined in vitro and in vivo work, both in chapter 2 and this section, unequivocally 
confirms that GM3+ AVNs could specifically target CD169+ APCs inside lymphatic 
system. With porous characteristic and high loading capacity embedded, GM3+ MS 
AVNs could further be utilized as delivery carrier other than just the tagging agent that 
has been investigated so far. 
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4.3 MS-AVNs as an Efficient Delivery Agent for RPV to Inhibit HIV-1: in vitro 
Studies  
So far, the scope of studies on AVNs has been limited for targeting studies, either like Au 
AVNs under the dark-field microscope, or like Gd-MS-AVNs under the MRI scanning. 
In this section, we will take MS-AVNs as the loading carrier to deliver RPV, a second-
generation non-nucleoside reverse transcriptase inhibitor of HIV-1 replication, to 
macrophages and myeloid dendritic cells.  
The choice of RPV is strongly favored by the hydrophobic nature shared by both MS-
AVNs and RPV molecule itself, which naively indicates RPV could be incorporated into 
MSN in a relatively convenient fashion (106). To test this hypothesis, we loaded the 
 
 
a). GM3-NPs administered to C57BL/6 mice through hock injection enrich in popliteal LNs in a 
GM3 dependent fashion. In the left mouse, GM3- and GM3+ Gd-MS-AVNs were injected into 
left and right hock respectively; in the right mouse, the left hock was injected with 1X PBS buffer 
while the right hock was injected with GM3+ Gd-MS-AVNs. The area where GM3+ Gd-MS-
AVNs enrich is marked out. b). The same mice but with different sectioning are given. c). The 
MRI sectioning of the mice pre-treatment is shown to give a background MRI level. 
Figure 4.4 MRI sectioning of Gd-MS-AVNs inside mice 
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MSNs with RPV simply by mixing the stock solution of RPV in acetonitrile (1mg/ml) 
with the MSN solution (1 × 1010 particles/ml) overnight. To assess antiviral efficacy of 
RPV-MS-AVNs against cell-free and cell-associated HIV infection, we either infected 
TZM-Bl cells, a HeLa cell-line could report and quantify the HIV-1 infection, or primary 
monocyte-derived macrophages (MDM) with wild type CCR5-tropic HIV-1/YU2, or co-
cultured TZM-Bl cells with HIV-1/YU2-exposed THP1/CD169 cells (cell-associated 
virus transfer model). Cells (TZM-Bl or MDMs) were treated with increasing 
concentrations of soluble RPV, RPV-loaded GM3-MS-AVNs (GM3-MS-RPV), or a 
long-acting formulation of RPV (LA-RPV (107)) prior to addition of virus particles, or 
co-culture with virus-exposed THP1/CD169 cells. In Figure 4.5, the inhibition curves for 
both cell-free (left) and cell-associated (THP-CD169 mediated, right) infection on TZM-
Bl cells with YU2 (CCR5-tropic HIV-1) in the presence of soluble RPV (blue), GM3-
MS-RPV (black) and LA-RPV (red) are given. As implied in Figure 4.5, the IC50 value, 
the concentration of an inhibitor where the HIV-1 amount is reduced by half, of GM3-
 
Inhibition curve of Cell-free (left) or THP-CD169-mediated cell-associated (right) infection of 
TZM-Bl cells with YU2 (CCR5-tropic HIV-1) in the absence and presence of increasing 
concentrations of soluble RPV, GM3-NP encapsulated RPV and LA-RPV. 
Figure 4.5 Inhibition curve of TZM-Bl cells. 
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MS-RPV is significantly lower than either soluble RPV or LA-RPV, at an order of 200-
fold and 10-fold respectively, indicating that RPV incorporation within GM3-MS-NPs 
dramatically enhanced antiviral potency of RPV in both cell-free infection of TZM-Bl 
and cell-associated trans infection in comparison to soluble RPV and LA-RPV. Similar 
enhancements to anti-viral potency were also observed in primary MDMs. In Figure 4.6, 
we show the inhibition curve on the primary MDMs (cell-free infection) in the presence 
of soluble RPV or GM3-MS-RPV. Again, the IC50 value of GM3-MS-RPV is about 200-
fold higher than soluble RPV, further highlights the anti-viral potency of GM3-MS-AVN 
formulated RPV.  
As LA-RPV is included here as a control, it is of essential interest to compare the 
inhibition effect of GM3-MS-AVN formulated RPV as a function of time with that of 
LA-RPV. To that end, we tracked the RPV inhibition effect on MDM infection (cell-free 
 
 
Cell-free infections (in triplicates) of MDMs with YU2 in the presence of RPV or GM3-NP-RPV.  
Figure 4.6 Inhibition curve of MDMs. 
 
MDM were treated with soluble RPV (10 nM) or GM3-NPRPV (1 nm) following infection with 
LaiΔEnv-luc/VSV-G on day 0, 1, 2 or 5 post ARV exposure. Cells were lysed 2 days post virus 
exposure and processed for quantification of luciferase activity (mean ± SD) 
Figure 4.7 Time dependent inhibition curve of MDMs. 
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approach) in a time-dependent fashion. MDMs were treated with RPV or AVN 
formulated RPV on day 0, and infected with luciferase expressing single cycle of 
replication competent HIV-1 reporter virus (LaiΔEnv-luc/VSV-G) on day 0,  day 1, day 2 
or day 5 post-addition of RPV. Figure 4.7 displays the luciferase activity (RLU) in 
infected-MDM cell lysate following infection with LaiΔEnv-luc/VSV-G. Interestingly, 
while soluble RPV only suppressed viral infection of MDM when added on the same day 
of infection (Day 0), sustained viral suppression (>99%) was observed for 5 days with 
GM3-NP-RPV (Figure 4.7). Combining the data in Figure 4.5, 4.6, 4.7, it is worthwhile 
pointing out that to date none of the prodrugs have reported such dramatic enhancements 
in antiviral potency, as described here. These results suggest that GM3-MS-AVNs are the 
ideal constructs for development of LA-nano-formulations that enhance the inhibitory 
effect of RPV for the treatment of HIV-1.  
4.4 Future Directions of MS-AVNs: Mechanism behind Potency and in vivo Work  
Even though GM3-MS-AVN formulated RPV show a potent anti-viral effect compared 
with soluble RPV or LA-RPV, the mechanism of enhanced potency remains unclear. In 
previous sections, it is assumed that the hydrophobicity nature shared by both MS-AVN 
core and the RPV molecule itself facilitates the incorporation of RPV into the MS-AVNs. 
In other words, with its hydrophobic characteristic, the loading of RPV into MS-AVNs is 
very efficient and such efficient loading out-competes the free-standing soluble RPV or 
LA-RPV in the delivery stage to the recipient cells. This assumption could be validated 
by inspecting the loading capacity of RPV in MS-AVNs in solvents with different 
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hydrophobicity, for example, in pure water, or with increasing concentrations of 
acetonitrile (20%, 50%, 75% and 100%) in water solution.   The amount of RPV inside 
the MS-AVNs could be analyzed with the aid of HPLC (108). However, inspecting the 
loading capacity just covers one end. For completeness, it is essential to investigate the 
releasing effect of RPV from those MS-AVNs in solvents with controlled 
hydrophobicity. Once those MS-AVNs enter the biological fluids, the co-existence of a 
large variety of proteins and bio-molecules makes it hard to define the hydrophobicity 
characteristic of biological fluids. Instead, the amount RPV in the cell lysate should be 
analyzed directly from soluble RPV, LA-RPV and GM3-MS-AVNs formulated RPV.  
As demonstrated in chapter 3, the presentation of GM3 on the AVN surface could trigger 
a unique trafficking pathway sequestering AVNs into VCCs, similar to HIV-1 particles. 
Thus, the control experiment in which GM3 is excluded from the MS-AVNs formulated 
RPV is of great interest to investigate the role of GM3 playing here.  
So far, in the previous sections, the study of RPV inhibition effect has been limited to the 
in vitro field, which already shows the superb potency and demonstrates that GM3-MS-
AVNs could serve as an excellent carrier for RPV. To develop GM3-MS-AVN 
formulated RPV for control of  HIV-1 replication, further in vivo work is necessary to 
validate such potency in an animal model.  
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MATERIALS & METHODS 
Liposome and AVN Preparation 
The lipid membrane and liposome was prepared as specified previously in chapter 2 and 
chapter 3. For the core of MS-AVNs, 25mg of meso-porous silica NPs (Sigma Aldrich) 
was added into 5ml 10% ethanol in water. Such solution was further tip-sonicated for 1hr 
and let stand still on bench for overnight. The supernatant solution, which contains 
relatively smaller sized MSNs was collected as the cores for AVNs. After that, the MSNs 
solution was mixed and co-incubated with prepared liposome solution for overnight. 
After that, the MS-AVNs were washed three times through centrifugation (2.4 krpm, 10 
min) and resuspended in Milli-Q water. Finally, the AVN pellet was resuspended in 200 
μL 20 mM HEPES buffer and ready to use. 
MS-AVNs administration in Mouse 
The mice were injected into both hocks with 10ul of Gd-MS-AVNs. The mouse on the 
left in Figure 4.4 received 4×106 Gd-MS-AVNs without GM3 into the left hock and the 
same amount GM3 containing Gd-MS-AVNs in the right hock. The mouse on the right of 
Figure 4.4 received PBS in the left hock and 4×106 GM3 containing Gd-MS-AVNs into 
the right hock.Both mice were sacrificed after 4h using CO2 and subsequent analyzed in 
the MRI. 
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Chapter 5 CONCLUSION AND FUTURE WORK 
With their advantageous size-controllable properties and ease of fabrication and surface 
modification, nanoparticles (NP) are becoming increasingly popular as a new tool for 
studying virus trafficking and delivering therapeutic agents into targeted recipient cells. 
In this thesis, we developed a novel lipid membrane wrapped NP system with tunable 
membrane composition and switchable core. Based on such versatile platform, we 
specifically utilize the GM3-CD169 recognition to fulfill the lipid mediated targeting 
towards myeloid macrophages and dendritic cells in the setting of HIV-1 infection and 
transfection. 
However, one great challenge for applications of all NPs in biological fluids is that a 
broad variety of different proteins can adsorb to the NP surface. The resulting formation 
of a so-called “corona” around an NP impacts the fate and distribution of NP both in vitro 
and in vivo due to nonspecific opsonization and scavenging. Here we show in this thesis, 
NP with a membrane composed of phospholipids, such as 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) could 
affect the corona formation and reduce the corona formation to a lower level, in vitro. 
The effect of the DPPC / DOPS ratio and the size of core is systematically analyzed and 
the optimized recipe for the membrane composition is given. With such optimized NP 
design, NPs were found to target CD169 expressing macrophages in the mouse lymph 
nodes in vivo. The in vivo work demonstrates that the lipid wrapped NP again represent a 
versatile platform for utilizing specific lipid–receptor interactions for targeting purposes. 
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The inclusion of GM3 provides not only specific GM3-CD169 targeting functionality but 
also allows to mimic the intracellular distribution observed for human immunodeficiency 
virus type 1 (HIV-1). Therefore, these lipid membrane coated NPs are referred to as 
artificial virus nanoparticles (AVN). We demonstrate that AVN can uniquely mimic the 
behavior of HIV-1 to accumulate in virus containing compartments (VCC), which are 
deep plasma membrane invaginations in macrophages that provide evasion for HIV-1 
from the immune system and anti-viral therapeutics. Through such VCC targeting 
finding, we further elucidated the antagonistic interplay roles between PS and GM3, both 
are enriched in lipid shell of various virus, such as HIV-1 and Ebola, in guiding NP into 
immune cells. The high concentration of PS lead AVNs follow the endosomal pathway 
while high input of GM3 favors the unique VCC pathway. Our findings suggest that 
GM3-presenting AVN provide a new platform for selectively targeting VCC associated 
HIV-1 reservoirs. Intrigiguingly, the ability to target VCC depended sensitively on the 
GM3/DOPS ratio of the AVN. 
Instead of just taking AVNs as the tagging tool, we then exchanged the gold NP core of 
AVN with a meso-porous silica NP, which serves as the matrix to carry therapeutic 
agents. In this way, we endow the AVN with delivery functions in addition to targeting 
specific recipient cells. We show using rilpivirine (RPV), a FDA approved second-
generation non-nucleoside reverse transcriptase inhibitor for the HIV infection treatment, 
that the meso-porous based AVN achieve significantly enhanced HIV-inhibition effects 
compared with pure RPV or commercialized long acting RPV compounds. In the future 
work, the mechanism that drives the enhanced inhibition effect shall be investigated to 
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determine if it is hydrophobicity or GM3 mediated. Furthermore, the assessment of HIV-
1 inhibition from GM3-MS-AVN formulated RPV should be extended to the in vivo 
work to validate such superb potency. Through combined in vitro and in vivo work, we 
could pave the way for a future rational design to eradicate HIV-1 from human immune 
cells with AVN-formulated antiretroviral drugs. 
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Appendix 1 DATA SOURCE FILES LOCATIONS RELATED TO ALL DATA 
SHOWN IN THIS THESIS 
 
Project 1: LIPID MEMBRANE WRAPPED NANOAPARTICLES: DESIGN, 
SYNTHESIS, CORONA FORMATION AND THEIR APPLICATIONS IN LIPID 
MEDIATED TARGETING 
Data source files location:  
https://drive.google.com/drive/folders/0B-qQDkzpNeiob3RmdVZKWVRqdWs?usp=sharing 
Project 2: MEMBRANE WRAPPED NANOPARTICLES FOR TARGETING 
VIRUS CONTAINING COMPARTMENTS: THE ANTAGONISTIC INTERPLAY 
BETWEEN GANGLIOSIDE GM3 AND PHOSPHATIDYLSERINE 
Data source files location:  
https://drive.google.com/drive/folders/0B-qQDkzpNeioT2kta3ZYRUIzcVE?usp=sharing 
Project 3: THERAPEUTIC TARGETING AND DELIVERY TOWARDS 
LYMPHATIC SYSTEM: MESO-POROUS SILICA BASED LIPID WRAPPED 
NANOPARTICLES 
Data source files location:  
https://drive.google.com/drive/folders/0B-qQDkzpNeiocUZDcTlZb2lSQlU?usp=sharing 
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